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A B S T R A C T
Background
The benefits and risks of antibiotics for acute bronchitis remain unclear despite it being one of the most common illnesses seen in
primary care.
Objectives
To assess the effects of antibiotics in improving outcomes and assess adverse effects of antibiotic therapy for patients with a clinical
diagnosis of acute bronchitis.
Search methods
We searched CENTRAL 2013, Issue 12, MEDLINE (1966 to January week 1, 2014), EMBASE (1974 to January 2014) and LILACS
(1982 to January 2014).
Selection criteria
Randomised controlled trials (RCTs) comparing any antibiotic therapy with placebo or no treatment in acute bronchitis or acute
productive cough, in patients without underlying pulmonary disease.
Data collection and analysis
At least two review authors extracted data and assessed trial quality.
Main results
Seventeen trials with 3936 participants were included in the primary analysis. The quality of trials was generally good. There was limited
evidence to support the use of antibiotics in acute bronchitis. At follow-up, there was no difference in participants described as being
clinically improved between antibiotic and placebo groups (11 studies with 3841 participants, risk ratio (RR) 1.07, 95% confidence
interval (CI) 0.99 to 1.15; number needed to treat for an additional beneficial outcome (NNTB) 22. Participants given antibiotics were
less likely to have a cough (four studies with 275 participants, RR 0.64, 95% CI 0.49 to 0.85; NNTB 6); have a night cough (four
studies with 538 participants, RR 0.67, 95% CI 0.54 to 0.83; NNTB 7) and a shorter mean cough duration (seven studies with 2776
participants, mean difference (MD) -0.46 days, 95% CI -0.87 to -0.04). The differences in presence of a productive cough at follow-
up and MD of productive cough did not reach statistical significance.
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Antibiotic-treated patientsweremore likely to be unimproved according to clinician’s global assessment (six studieswith 891 participants,
RR 0.61, 95% CI 0.48 to 0.79; NNTB 25); have an abnormal lung exam (five studies with 613 participants, RR 0.54, 95% CI 0.41
to 0.70; NNTB 6); have a reduction in days feeling ill (five studies with 809 participants, MD -0.64 days, 95% CI -1.16 to -0.13) and
a reduction in days with limited activity (six studies with 767 participants MD -0.49 days, 95% CI -0.94 to -0.04). The differences in
proportions with activity limitations at follow-up did not reach statistical significance. There was a significant trend towards an increase
in adverse effects in the antibiotic group (12 studies with 3496 participants) (RR 1.20, 95% CI 1.05 to 1.36; NNT for an additional
adverse effect 5).
Authors’ conclusions
There is limited evidence to support the use of antibiotics in acute bronchitis. Antibiotics may have a modest beneficial effect in some
patients such as frail, elderly people with multimorbidity who may not have been included in trials to date. However, the magnitude of
this benefit needs to be considered in the broader context of potential side effects, medicalisation for a self-limiting condition, increased
resistance to respiratory pathogens and cost of antibiotic treatment.
P L A I N L A N G U A G E S U M M A R Y
Antibiotic treatment for people with a clinical diagnosis of acute bronchitis
Acute bronchitis is a clinical diagnosis for an acute cough, which may or may not be productive of mucus or sputum. It occurs when
the tubes (bronchi) within the lungs become inflamed and may be caused by viruses or bacteria. Symptoms generally last for two weeks
but the associated cough can last for up to eight weeks. Recently, there has been controversy over the term acute bronchitis as it covers
a range of clinical presentations that may overlap with other diagnoses such as upper or lower respiratory tract infections. For this
reason, some have suggested using the term ’acute lower respiratory tract infection when pneumonia is not suspected’ as this is more
specific. Antibiotics are commonly prescribed to treat this condition though other treatments providing symptom relief are commonly
used. Antibiotics can have adverse effects such as nausea and diarrhea but can cause more serious reactions related to anaphylaxis in
those allergic to them. In healthy communities, there is little evidence of bacterial infection in people with bronchitis and there is no
practical test to distinguish between bacterial and viral bronchitis. Within this context the use of antibiotics to treat acute bronchitis is
controversial but common. Concerns that prescribing unnecessary antibiotics increases antibiotic resistance exists.
We included 17 trials with 3936 participants diagnosed with acute bronchitis and randomly assigned to receive any antibiotic treatment
or a placebo or no treatment. Co-treatments with other medications to relieve symptoms were allowed if they were given to all patients.
We excluded patients with pre-existing underlying pulmonary disease such as chronic bronchitis or chronic obstructive pulmonary
disease. The quality of trials was generally good, particularly for more recent studies. There was limited evidence to support the use
of antibiotics for acute bronchitis and a large study involving 1038 patients from 12 countries included in this update has confirmed
this finding. Some people treated with antibiotics recovered a bit more quickly with reductions in cough-related outcomes though the
difference was of doubtful clinical significance as it amounted to a difference of half a day over an 8 to 10 day period. There was a
statistically significant but small increase in adverse side effects in patients treated with antibiotics. The most commonly reported side
effects included nausea, vomiting or diarrhea, headaches, skin rash and vaginitis.The available evidence suggests that there is no benefit
in using antibiotics for acute bronchitis in otherwise healthy individuals though more research is needed on the effect in frail, elderly
people with multimorbidities who may not have been included in the existing trials. The use of antibiotics needs to be considered in
the context of the potential side effects, medicalisation for a self-limiting condition and costs of antibiotic use, particularly the potential
harms at population level associated with increasing antibiotic resistance.
B A C K G R O U N D
Description of the condition
Acute bronchitis is a common illness which is characterised by
fever and cough that is often wheezy in nature and the cough
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may or may not be productive. Acute bronchitis occurs when the
bronchi become inflamed and it may be caused by either viral or
bacterial infection. Symptoms generally last for two weeks but the
associated cough can last for up to eight weeks (CDC 2013). It
is the ninth most common among outpatient illnesses recorded
by physicians in ambulatory practice in the USA (Delozier 1989)
and the fifth most commonly encountered by Australian General
Practitioners, forwhom it represents 3.5%of encounters and 2.4%
of problems seen (Meza 1994). In the UK, there are 300 to 400
consultations for treatment of respiratory tract infections per 1000
registered patients each year and while antibiotic prescribing for
these conditions had declined between 1995 and 2000, it has
since stabilised (Gulliford 2011). TheEuropeanCentre forDisease
Prevention and Control provides data on trends in antimicrobial
consumption across Europe suggesting that overall antibiotic use
varies across Europe with most countries showing increases over
the period 1997 to 2010 (ECDC 2013).
Population-based estimates of the incidence of acute bronchitis
range from 33 to 45 cases per 1000 per year (Ayres 1986;Mainous
1996). Patients with bronchitismiss an average of two to three days
off work per episode. The great majority of episodes of acute bron-
chitis in healthy individuals are presumed to be viral infections, al-
though this has been questioned (Macfarlane 1994). Community-
based studies have isolated viruses in 8% to 23% of cases (Boldy
1990; Macfarlane 1993; Stuart-Harris 1965). Other pathogens
implicated in acute bronchitis are Mycoplasma pneumoniae (M.
pneumoniae), Chlamydia pneumoniae (C. pneumoniae) and Borde-
tella pertussis (B. pertussis), each of which has been identified in up
to 25% of cases in various populations (Boldy 1990; Falck 1994;
Foy 1993; Grayston 1993; Herwaldt 1991; Jonsson 1997; King
1996; Macfarlane 1993; Robertson 1987; Stuart-Harris 1965;
Thom 1994). A more recent study assessing the aetiology and out-
come of acute lower respiratory tract infection in 638 adults in
UK primary care, showed that in 55% viral or bacterial pathogens
were identified (Macfarlane 2001).
Description of the intervention
The use of antibiotics for patients with acute bronchial infec-
tions remains a controversial area in primary health care prac-
tice (Coenen 2007; Gonzales 1995). Streptococcus pneumoniae (S.
pneumoniae), Haemophilus influenzae (H. influenza) andMoraxella
catarrhalis (M. catarrhalis) have been isolated from sputum sam-
ples in up to 45% of patients with acute bronchitis (Henry
1995; Macfarlane 1993) but their role is difficult to assess be-
cause of potential oropharyngeal colonisation in healthy individu-
als (Laurenzi 1961; Smith 1986). Unfortunately, there are no clin-
ically useful criteria that accurately help distinguish bacterial from
viral bronchial infections. Therefore, some authors have called
for physicians to stop prescribing antibiotics for patients with
acute bronchitis (Gonzales 1995; Hueston 1997). Nonetheless,
antibiotics are prescribed for 60% to 83% of patients who present
to physicians with this disorder (Gonzales 1997; Mainous 1996;
Meza 1994; Petersen 2007; Straand 1997). Overall antibiotic use
varies across Europe with most countries showing increases over
the period 1997 to 2010 (ECDC 2013).
How the intervention might work
Antibiotics may improve outcomes in acute bronchitis if the dis-
ease is caused by a bacterial infection. They have no antiviral activ-
ity so are not effective in viral bronchitis. In addition, antibiotics
can cause harm relating to their adverse effect on normal bacteria
colonising the intestine. These adverse effects most commonly in-
clude gastrointestinal symptoms such as nausea and diarrhea but
antibiotics can also cause more serious reactions related to ana-
phylaxis in those allergic to them.
Why it is important to do this review
As acute bronchitis occurs so frequently, it is important to obtain
some estimate of the probable effectiveness of antibiotic therapy.
If effective, antibiotics could shorten the course of the disease and
reduce the loss of productive work time it causes. However, any
benefit from antibiotics must be weighed against the possibility
that excessive antibiotic usewill lead to increases in cost andpatient
morbidity, as well as development of resistant strains of common
organisms (Coenen 2007; Molstad 1992) and unnecessary medi-
calisation of individuals with a self-limiting illness (Little 2005). If
antibiotics are ineffective, then their use should be discontinued.
O B J E C T I V E S
Toassess the effects of antibiotics in improving outcomes and assess
adverse effects of antibiotic therapy for patients with a clinical
diagnosis of acute bronchitis.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomised controlled trials (RCTs) in patients with acute bron-
chitis assigned to treatment with an antibiotic or a placebo or no
active treatment.
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Types of participants
We included trials that included patients of either sex or any age
with a clinical syndrome of cough with or without productive
sputum, with a physician’s diagnosis of acute bronchitis or cough
with persistent cold or flu-like illness that was not resolving. The
term “acute lower respiratory tract infection when pneumonia is
not suspected” is also used to describe this clinical presentation.
We excluded trials that included patients with pre-existing chronic
bronchitis (i.e. acute exacerbation of chronic bronchitis).
Types of interventions
We included all RCTs comparing any antibiotic therapy versus no
treatment or placebo in the management of acute bronchitis. We
excluded trials comparing one antibiotic regimen with another, or
trials comparing the use of other active medications (such as bron-
chodilators) with antibiotic therapy in this review. We included
trials that allowed concurrent use of other medications such as
analgesics, antitussives, antipyretics or mucolytics if they allowed
equal access to such medications for patients in the antibiotic and
control groups.
Types of outcome measures
We included the following range of cough-related and general
clinical outcomes.
Primary outcomes
1. Cough-related outcomes including:
i) time to resolution of cough;
ii) sputum production, defined as proportion of patients
with or without sputum;
iii) proportions of patients with cough, night cough,
productive cough.
2. Global assessment of improvement by clinicians at follow-
up.
3. General clinical outcomes including:
i) severity of symptoms;
ii) activity limitations;
iii) abnormal lung examination at a designated follow-up
visit.
Secondary outcomes
1. Adverse effects.
Search methods for identification of studies
Electronic searches
For this updated review, we searched the Cochrane Central Regis-
ter of Controlled Trials (CENTRAL) 2013, Issue 12, part of The
Cochrane Library, www.thecochranelibrary.com (accessed 15 Jan-
uary 2014), which includes the Acute Respiratory Infections (ARI)
Group’s Specialised Register, MEDLINE (1966 to January week
1, 2014), EMBASE (1974 to January 2014) and LILACS (1982 to
January 2014). We used the search strategy described in Appendix
1 to search MEDLINE and CENTRAL. The search strategy was
adapted to search EMBASE (Appendix 2) and LILACS (Appendix
3). Details of the 2007 update search are in Appendix 4.
Searching other resources
We searched theWHO International Clinical Trials Registry Plat-
form and ClinicalTrials.gov (19 February 2013). We also searched
the reference lists of relevant trials, review articles and textbook
chapters to identify additional trials, including those published
prior to 1966; and we included articles from the authors’ personal
collections. We also requested unpublished trials from trial au-
thors. In addition, we also contacted drug companies that manu-
facture antibiotics for the earlier version of this review. There were
no language or publication restrictions.
Data collection and analysis
Selection of studies
For the original review (Becker 1997), two authors (LB and JS) in-
dependently used the titles and abstracts of the identified citations
to exclude trials that clearly did not meet the inclusion criteria of
the review. The full paper was obtained for further examination
if either review author felt that the trial might possibly meet the
criteria. The most common reasons for exclusion were the lack of
a control group receiving a placebo, or the inclusion of patients
with chronic bronchitis.
Three review authors (LB, JS, TF) reviewed articles, which passed
this initial screen by using only the method section of each paper,
without reference to the names of the authors, the institution, the
journal or the results, to determine their fit with the inclusion
criteria for this review. Nine articles passed this second screen but
only eight had extractable data. We obtained unpublished data
from the other trial (Hueston 1994) from the trial author.
For review updates, two authors screened citations after an up-
dated search was carried out by the Acute Respiratory Infections
(ARI) Group for the 2004 update of this review (Fahey 2004). We
incorporated two RCTs that met the inclusion criteria into the
review. An updated search was carried out by the ARI Group for
the 2009 update of the review (Smith 2009). Two review authors
(TF, SS) identified and screened three potentially eligible papers
and one additional study was included (Little 2005). The ARI
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Group updated the searches for the Smith 2011 update and one
additional eligible study was included (Nduba 2008).
For this 2014 updated review, two review authors screened and
identified one new eligible study (Little 2013) and one ongoing
study (Stocks 2013). One of the ongoing trials has been published
and is also included in the review (Llor 2013).
Data extraction and management
More than one review author independently extracted data from
original studies for each update of this review. We resolved dis-
agreements by discussion between the review authors.
Assessment of risk of bias in included studies
Three review authors (LB, KJS, TF) evaluated the methodologi-
cal quality of each trial, while remaining blinded to the names of
the trial authors, the institution and the journal in which the trial
was published. For previous versions of the review, we assessed
the methodological quality of each trial using a scoring system
described by Chalmers (Chalmers 1990), which assigned points
for randomisation method, blinding of outcome assessment and
of patients, intention-to-treat (ITT) analysis, contamination and
co-intervention and losses to follow-up. Agreement among the re-
view authors regarding the quality of the articles was high. Dis-
agreements were resolved by discussion and consensus.
For the 2009 update, two review authors (SS, TF) reassessed the
original quality of all included studies by using the new ’Risk of
bias’ guidelines and incorporated this into the ’Risk of bias’ tables
now presented in this updated review. Two review authors (SS,
TF) screened the studies added in the 2011 and 2013 updates.
Measures of treatment effect
The effect measures of choice were risk ratio (RR) for categorical
outcomes and mean difference (MD) for continuous data.
Unit of analysis issues
There were no cluster-randomised trials included in this review as
it involved a simple drug trial with a placebo comparator. Clini-
cians were generally blinded to the intervention. We identified no
unit of analysis errors.
Dealing with missing data
Where data were missing this was reported within the risk of bias
section. We did not adopt any strategies to deal with missing data
such as imputation. In general, missing data did not bias the review
findings.
Assessment of heterogeneity
Where clinical heterogeneity was considered to be an issue, we un-
dertook a random-effects meta-analysis rather than a fixed-effect
meta-analysis. This particularly applied to themost recent analysis
added to this updated version of the review (Analysis 6.1).
Assessment of reporting biases
We examined funnel plots for each of the included analyses and
none indicated any significant level of reporting bias.
Data synthesis
All previous versions of this review have presented fixed-effect
meta-analyses. For this update, we included a range of outcomes
under the broad definition of ’clinically improved’. These were
clinically heterogeneous so we used a random-effects meta-analy-
sis.
Subgroup analysis and investigation of heterogeneity
We also carried out a subgroup analysis comparing studies using
a placebo control or no active treatment.
Sensitivity analysis
We included only studies that limited enrolment to patients with
a clinical diagnosis of acute bronchitis or acute productive cough
for the primary analysis. We did a sensitivity analysis that included
unpublished data from subgroups of patients with a productive
cough (Howie 1970) and non-purulent tracheobronchitis (Kaiser
1996) from two studies that enrolled patients with an influenza-
like illness or a common cold.
R E S U L T S
Description of studies
Results of the search
The updated and modified CENTRAL, MEDLINE, EMBASE
and LILACS searches in 2014 yielded an additional 799 titles. All
of the 17 trials included in the primary analysis enrolled patients
with a diagnosis of acute cough or acute lower respiratory tract
infection. In one study (Franks 1984), patients were required to
produce a sputum sample for analysis as a condition of enrolment.
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Included studies
For this 2014 update, two new studies were added (Little 2013;
Llor 2013). These were important additions, particularly the trial
by Little 2013 as it is the largest trial conducted to date and in-
cluded 2061 patients recruited across 12 countries. Patients were
randomised to receive amoxicillin or placebo and there was low
risk of bias with more than 80% follow-up of participants.
For most studies, clinical findings were used to exclude patients
thought to have pneumonia. Four studies included chest radio-
graphs in their protocols - two (Brickfield 1986; Nduba 2008)
performed a chest film on all potential participants. In the other
two, Scherl 1987 did so on patients with rales or fever and Llor
2013 did so on cases with suspected pneumonia (seven of 416
participants). Both excluded those with radiological evidence of
pneumonia or tuberculosis (TB).One study (Stott 1976) excluded
patients with any abnormality noted on examination of the chest.
Four trials also excluded patients with a clinical syndrome suggest-
ing sinusitis (Dunlay 1987; King 1996; Verheij 1994; Williamson
1984).
In all trials, the duration of illness at entry was less than 30 days.
One trial (Stott 1976) limited enrolment to patients ill for less
than one week; in five trials the duration was two weeks or less
(Brickfield 1986; Evans 2002; Franks 1984; King 1996; Matthys
2000).
Eight of the trials included only adults (Brickfield 1986; Dunlay
1987;Hueston 1994; Little 2013; Llor 2013;Nduba 2008;Verheij
1994; Williamson 1984). The remaining studies included adoles-
cents plus adults (Franks 1984; Scherl 1987; Stott 1976) or pa-
tients aged three years (Little 2005) or eight years or older (King
1996).
As for antibiotic treatment, four trials (Scherl 1987; Stott 1976;
Verheij 1994; Williamson 1984) used doxycycline, four ery-
thromycin (Brickfield 1986; Dunlay 1987; Hueston 1994; King
1996), one trimethoprim/sulfamethoxazole (Franks 1984), one
azithromycin (Evans 2002), one cefuroxime (Matthys 2000), one
amoxicillin or erythromycin (Little 2005), two amoxicillin (Little
2013; Nduba 2008) and one co-amoxiclav (Llor 2013).
The majority of studies used a single reassessment visit to evaluate
results of the intervention. The timing of this visit varied from
study to study, ranging from two to 14 days after the initiation of
treatment. Some investigators also asked patients to keep symptom
diaries, which were used to determine the duration of symptoms
or disability.
Several of the trials provided results of separate analyses of one or
more subsets of patients based on characteristics such as cigarette
smoking, patient age, duration of symptoms, presence of puru-
lent sputum or illness severity. All patients enrolled in the study
by Nduba 2008 were tested for HIV. We have only included re-
sults relating to the subgroup of patients who tested negative. The
largest study included in the review, which was incorporated in
the current update (Little 2013), was adequately powered for a
subgroup analysis of patients aged over 60 years.
For the sensitivity analyses, we included unpublished data from
two trials. In one (Howie 1970), patients began self-treatment
with dimethyl chlortetracycline or placebo if a cold or influenza-
like illness was not spontaneously resolving after two days. We
included data from a subgroup of patients who had a produc-
tive cough prior to beginning treatment. The other study (Kaiser
1996) randomised patients with the common cold to amoxicillin-
clavulanic acid or placebo.We included data from a subgroup who
had a concomitant diagnosis of non-purulent tracheobronchitis,
which incorporates ’acute bronchitis’. Further details on the sub-
groups of patients included from these studies is provided in the
Characteristics of included studies table.
Excluded studies
Studies were excluded for a variety of reasons based on study design
and intervention criteria. Full descriptions of such exclusions are
detailed in the Characteristics of excluded studies table.
Risk of bias in included studies
Sixteen of the 17 included trials were randomised, double or sin-
gle-blind evaluations comparing an antibiotic with a placebo. The
study added for the 2011 update (Nduba 2008)was the first equiv-
alence RCT included in the review. The earlier study by Little
2005 involved three arms comparing immediate antibiotic ther-
apy, no active treatment or delayed treatment and we included
the two arms comparing immediate antibiotic treatment with no
treatment only. The study by Llor 2013 added to the current up-
date, involved three arms comparing antibiotic, placebo and anti-
inflammatory treatment; we included data from the antibiotic ver-
sus placebo arms. Four reports (Brickfield 1986; Howie 1970;
Kaiser 1996; Scherl 1987) did not clearly state the randomisation
method used. Only one of the articles (Nduba 2008) reported a
formal evaluation of the effectiveness of the blinding procedures
used. Compliance or adherence with treatment was measured in
six studies; in five, there were no differences in the number of
pills taken in the antibiotic and placebo groups (Dunlay 1987;
Hueston 1994; Little 2013;Nduba 2008; Stott 1976); in the study
by King 1996, 94% of the patients who returned for follow-up
took at least one-half of their pills and Little 2013 reported > 90%
adherence in both groups by day five. Regarding co-interventions
with other medications, four trials asked patients to record the use
of non-prescription medications and included this as an outcome
measure (Dunlay 1987; Franks 1984; Hueston 1994; King 1996);
one restricted use to aspirin and acetaminophen, but did not have
the patients record this (Scherl 1987); and one reported adjunc-
tive prescriptions, but not use of over-the-counter medications
(Verheij 1994). The majority of studies (13 out of 17) followed up
more than 80% of participants (details of drop-outs are provided
in the Characteristics of included studies table). In some cases,
no information about withdrawals was available in the paper or
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from the authors. However, when information was available, we
included outcome data from the last point at which the patients
were still in the study. As far as possible, we analyzed patients on
an intention-to-treat basis.
The overall risk of bias is presented graphically in Figure 2 and
summarised in Figure 3.
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Figure 2. ’Risk of bias’ summary: review authors’ judgements about each methodological quality item for
each included study.
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Figure 3. ’Risk of bias’ graph: review authors’ judgements about each methodological quality item
presented as percentages across all included studies.
Allocation
In general, there wasminimal risk of allocation or selection bias; 15
out of 17 studies clearly reported adequate allocation concealment.
Blinding
In general, there was minimal risk of bias relating to lack of blind-
ing with 14 out of 17 studies clearly reporting adequate blinding
of outcome assessors.
Incomplete outcome data
Themajority of studies had adequate completion of outcome data
and there was minimal risk of attrition bias.
Selective reporting
Most trials evaluated several different outcome measures. In some
cases, the published reports included detailed data for only those
outcomes found to be statistically significant. To minimise this
reporting bias, we attempted to obtain additional data from the
trial authors; five authors provided this information (Howie 1970;
Hueston 1994; Kaiser 1996; King 1996;Williamson 1984).How-
ever, we were still unable to include data from Stott 1976 for the
outcomes of cough, night cough or activity limitations at follow-
up, which were reported in the published trial as being not signif-
icantly different between groups.
Other potential sources of bias
The main concern regarding bias was the relatively small numbers
of studies that could be included in individual meta-analyses. We
have attempted to address this by adding a new broader analysis re-
flecting clinical improvement. This has been further strengthened
by the addition of the largest multi-country trial to date (Little
2013). There were no additional concerns regarding other poten-
tial sources of bias.
Effects of interventions
The same outcomemeasures were not reported in all studies. Some
studies reported the presence or absence of various symptoms and
signs at a follow-up visit; others reported the mean duration of
symptoms; and still others reported only unique symptom scores.
Also, in some studies explicit data were available only for outcomes
that were significantly different between the antibiotic and placebo
groups. Therefore, the number of studies that provide data for
the outcomes in this review ranged from three to 11. None of the
summary outcomes in the primary analysis exhibited statistically
significant heterogeneity apart from the analysis of patient ’clini-
cally improved’. Numbers of studies and participants included in
the individual meta-analyses are generally small, though the meta-
analysis for ’clinically improved’ includes 11 studies and the meta-
analysis for adverse events includes 12 studies.
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Primary outcomes
1. Cough-related outcomes
At the follow-up visit, patients given antibiotics were less likely to
have a cough (4 studies with 275 participants, risk ratio (RR) 0.64,
95% CI 0.49 to 0.85, NNT 22) (Analysis 1.1; Figure 4) or have
a night cough (4 studies with 538 participants, RR 0.67, 95% CI
0.54 to 0.83,NNT7) (Analysis 2.1). The differences in presence of
a productive cough at follow-up and days of productive cough did
not reach statistical significance. Antibiotic-treated patients only
had a significant reduction in mean duration of cough when the
study by Little 2005, which had a no treatment comparison group,
was excluded (Figure 5). Llor 2013 also reported no significant
difference in the median days of cough between the antibiotic and
placebo group. Sensitivity analysis also altered the outcome for
the mean duration of productive cough, which was significantly
reduced if theHowie 1970 study relating to upper respiratory tract
infection was excluded.
Figure 4. Forest plot of comparison: Cough at follow-up visit, outcome: number of patients with cough.
Figure 5. Forest plot of comparison: 8 Days of cough, outcome: mean number of days of cough.
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2. Global assessment of improvement by clinicians at follow-
up: ’clinically improved’
For the 2011 update of the review, we included an additional
analysis that included a broader outcome ’clinically improved’,
so that as many studies as possible could be included in a meta-
analysis. This was particularly important following the inclusion
of the Nduba 2008 study in 2011, which was of high quality,
included a large number of participants and showed no benefit
from antibiotic use. This has been updated and includes additional
data from the authors of the largest included study, added to this
2013 update (Little 2013). The data from Little 2013 is based
on numbers of patients no longer reporting their symptoms being
’moderately bad’ at one week. The published study presents mean
symptom severity scores in the first few days, which indicated no
significant difference between the intervention and control groups
(Little 2013). This outcome reflects the proportions of patients
with clinical improvement and incorporates ’cure’ as measured by
a > 75% reduction in the Acute Bronchitis Severity Score (Nduba
2008), global improvement or being well (Brickfield 1986; Llor
2013;Matthys 2000; Stott 1976;Verheij 1994;Williamson1984),
patient report of no limitations (Dunlay 1987; Evans 2002; Franks
1984) and resolution of symptoms rated as moderately bad, severe
or worsening (Little 2013). This analysis includes 11 studies and
3841 participants and shows no statistically significant difference
(RR 1.07, 95% CI 0.99 to 1.15, NNT 22) (Analysis 6.1; Figure
1). This is essentially unchanged since the last version of the review
although the addition of the data from Little 2013 and Llor 2013
has increased the heterogeneity. A sensitivity analysis removing the
studies reporting ’no limitation’ made no difference to this result.
3. General clinical outcomes
Antibiotic-treated patients also had a reduction in the number of
days feeling ill (5 studies with 809 participants, mean difference
(MD) -0.64, 95% CI -1.16 to -0.13) (Analysis 8.1; Figure 6) and
a reduction in days with impaired activity (6 studies with 767
participants, MD -0.49, 95% CI -0.94 to -0.04) (Analysis 9.1).
There was no significant difference in proportions of patients with
activity limitations at follow-up. Patients on antibiotics were more
likely to be unimproved by the clinician’s global assessment (6
studies with 891 participants, RR 0.61, 95% CI 0.48 to 0.79,
NNT 25) (Analysis 10.1; Figure 7) and have an abnormal lung
exam (5 studies with 613 participants, RR 0.54, 95% CI 0.41 to
0.70, NNT 6) (Analysis 11.1). Additional clinical outcomes were
reported by Little 2013 who found no significant difference in
mean symptom severity scores on days two to four (intervention
score 1.62 (standard deviation (SD) 0.84) versus control score 1.69
(SD 0.84), P = 0.07) and Evans 2002 found that azithromycin
had no benefit in terms of health-related quality of life at day three
and day seven follow-up. Llor 2013 also reported no difference in
time to overall symptom resolution between groups.
Figure 6. Forest plot of comparison: Days of feeling ill, outcome: mean number of days of feeling ill.
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Figure 7. Forest plot of comparison: Not improved by physician’s global assessment at follow-up visit,
outcome: number of patients not improved.
Secondary outcomes
1. Adverse effects
With four exceptions (Brickfield 1986; Little 2005;Matthys 2000;
Nduba 2008), all of the studies found that patients in the antibiotic
group reported more adverse effects than did patients receiving a
placebo (Figure 8). The RR of adverse effects in the antibiotic-
treated group was statistically significant at 1.20 (12 studies with
3496 participants, 95% CI 1.05 to 1.36, NNT 5) (Analysis 12.1).
Themost commonly reported side effects involved gastrointestinal
symptoms such as nausea, vomiting or diarrhea. Headaches, skin
rash and vaginitis also occurred. Side effects seemed mild as only
0% to 13% (overall 3.7%) of volunteers withdrew for this reason
and no deaths were reported.
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Figure 8. Forest plot of comparison: Number of patients with adverse effects.
Subgroups
We were not able to obtain enough explicit data from the studies
for various patient subgroups, therefore we did not carry out any
sensitivity analyses based on patient characteristics (such as age,
duration of illness or smoking status). Little 2013 was adequately
powered to assess the effect in the subgroup of patients aged over
60 and found no significant benefit in this group. The results in
the individual studies for subgroup analyses were mixed. In one
trial, all of the significantly improved outcomes from antibiotics
occurred in non-smokers (Brickfield 1986). The other seven trials
reported that they found no differences in antibiotic effectiveness
for smokers versus non-smokers but included no data on these
comparisons in their published reports. Verheij 1994, using multi-
ple regression, found that two subsets of patients were more likely
to improve with doxycycline than placebo: patients over 55 years
and patients with very frequent cough who felt ill. Scherl 1987
found that only patients without coryza or sore throat had fewer
days of cough or sputum with doxycycline. The only study to use
Gram stains (Franks 1984) reported an earlier return to work for
patients with a positive Gram stain who were treated with antibi-
otics. Nduba 2008 also examined whether use of amoxicillin was
more effective than placebo in patients who had tested positive for
HIV and found no difference, though all patients had received a
chest X-ray and those with any abnormal signs were excluded.
Little 2005 was added to the 2009 update and found no significant
difference in outcomes between groups treated with immediate
antibiotics compared with no antibiotic treatment. As this study
did not involve a placebo control we included it in the analyses,
where appropriate data were available, as a subgroup to highlight
this difference. The one study included in the 2011update (Nduba
2008) was powered to detect equivalence between antibiotic and
placebo and found no significant difference. In fact, the point es-
timates favoured placebo treatment (84% cured on placebo versus
82.4%% cured on amoxicillin). The largest included study, which
was added in the 2013 update, was included in the meta-analyses
of ’clinically improved’ and adverse effects (Little 2013).
D I S C U S S I O N
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Summary of main results
There are mixed results across studies with some suggesting mar-
ginal benefits for antibiotics, though these are of doubtful clini-
cal significance. However, the inclusion of the largest multi-centre
study of the effectiveness of antibiotics in patients with lower res-
piratory tract infections strengthens the evidence and also high-
lights a statistically significant increase in adverse events in the an-
tibiotic-treated groups. However, it is possible that older patients
with multimorbidities may not have been recruited to trials so the
evidence guiding decision making in this group of patients is less
certain.
Overall completeness and applicability of
evidence
In general, the available evidence suggests we should not be using
antibiotics to treat acute bronchitis or lower respiratory tract in-
fections when pneumonia is not expected. There is a modest ben-
efit from antibiotics for some outcomes but these are of minimal
clinical significance. Any benefit is even less apparent in the sen-
sitivity analysis, which included data from subgroups of patients
with productive cough of short duration (two to four days) in con-
junction with the common cold. Of the two trials in the primary
analysis that limited enrolment to patients who had been ill for
less than one week, one did not show any benefit from antibiotics
(Stott 1976), whilst the other showed modest benefit with antibi-
otic (Matthys 2000).
It is possible that the overall benefit noted from antibiotics resulted
from the inclusion in some trials of patients who may have had
pneumonia instead of acute bronchitis. There was variation be-
tween studies on whether chest X-rays were conducted as part of
evaluations. Only one trial (Brickfield 1986) obtained chest radio-
graphs on all patients and then excluded those whose films were
consistent with pneumonia. In Little 2013, a positive chest X-
ray was not an automatic exclusion criteria though some patients
dropped out following such a finding and further publications on
this are planned (author communication). All other studies either
excluded or obtained chest radiographs in patients with clinical
findings of suspected pneumonia (which inmost studies were focal
findings on chest examination). Individual signs (such as crackles
or fever) are not sensitive (Metlay 1997a), therefore their absence
cannot be relied on to rule out pneumonia. On the other hand,
since the prevalence of pneumonia in outpatients who present
with cough is generally low (less than 5% in the USA) (Metlay
1997b), it is unlikely that a significant number of patients in these
trials had pneumonia. Further evidence for this is that only three
patients who were randomised to placebo among all nine primary
trials were subsequently diagnosed with pneumonia (two patients
in Stott 1976 and one in Scherl 1987). In addition, this review is
designed to test the effectiveness of treatment for acute bronchitis
in clinical practice and it is not standard practice to confirm the
diagnosis of acute bronchitis with a chest X-ray unless there is a
clinical suspicion of underlying pneumonia. If we had only in-
cluded studies with chest X-ray confirmation of diagnosis it would
have limited the generalisability of the review findings.
Quality of the evidence
Since there is no gold standard test, the diagnosis of acute bronchi-
tis must be made on clinical grounds. All of the trials excluded pa-
tients with chronic pulmonary disease and enrolled patients with
recent onset of a respiratory illness with a productive cough. The
results of the studies in the primary analysis that included patients
with a productive cough, without specifically stating that the pa-
tients had acute bronchitis, were similar to the studies that used
this specific terminology, as one showed some benefits from antibi-
otics (Verheij 1994) and one did not (Stott 1976). Clinical char-
acteristics of patients did vary somewhat among studies regarding
the duration of illness and associated symptoms and physical find-
ings but were consistent with definitions generally used by pri-
mary care physicians (Oeffinger 1997; Verheij 1990). Therefore,
these results would appear to be generalisable to the management
of acute bronchitis in community practices.
Potential biases in the review process
This review may also be subject to bias because although we have
now included 16 trials and 3656 participants, it is possible that
some patient subgroups are under-represented as they may not
have been recruited into the original trials. Little 2013 points out
that while they included a large sample of older patients, more
severely ill older people with multimorbidities were unlikely to
have been approached to participate in the trial and in these types
of patients, their results should be interpreted with caution and
this applies to the review results also.
Agreements and disagreements with other
studies or reviews
In the current update of the review, we have included a largemulti-
country trial that shows no benefits from antibiotics even in older
patients. Further analyses of the data from this study are ongo-
ing as part of Workpackage 10 of the GRACE program (http://
www.grace-lrti.org). It should be noted that a recent large obser-
vational study examining symptom resolution in 2714 patients
with acute cough who had been prescribed amoxicillin across 13
European countries found that symptom resolution was quicker
in those receiving no antibiotic (Butler 2010).
A U T H O R S ’ C O N C L U S I O N S
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Implications for practice
This review confirms the impression of clinicians that antibiotics
have limited, if any, beneficial effects in acute bronchitis. Where
there appear to be some benefits, they are slight (such as the small
improvement in mean duration of cough of less than one day) and
may be of questionable clinical significance. The most recently
published placebo-controlled randomised controlled trial (RCT)
confirms these findings and was carried out in 12 countries, im-
proving the generalisability of the review findings (Little 2013).
The RCT included in the last update of the review in 2011 also
showed no difference in cure rates between those prescribed amox-
icillin and those given placebo (Nduba 2008). This trial was par-
ticularly important as it was set in a low-income country and may
increase the generalisability of the review. However, the inclusion
of a range of trials in different settings does also increase hetero-
geneity.
While this review suggests limited if any benefit from antibiotics,
one could argue for prescribing antibiotics for acute bronchitis
because studies of patient utilities for antibiotic treatment for res-
piratory infections suggest that even small benefits are seen as im-
portant by some patients (Herman 1984) and because the adverse
effects associated with antibiotic treatment are minor and disap-
pear when the medication is discontinued. On the other hand,
arguments against prescribing antibiotics can be made because the
modest benefits from antibiotics may not outweigh their costs,
adverse effects or negative consequences on antibiotic resistance
patterns and patient expectations. Also, as noted above, the cur-
rent update provides clearer evidence on the lack of effectiveness
of antibiotics for acute bronchitis.
It is likely that, as with other respiratory infections (Dagnelie 1996;
Kaiser 1996), antibiotics may be only effective for a subset of pa-
tients with acute bronchitis. It seems that patients who have other
typical symptoms of an upper respiratory tract infection and who
have been ill for less than one week may be the least likely to ben-
efit from antibiotics. A large recent cohort study within the UK
General Practice Research Database has indicated that the risk of
pneumonia as a complication of lower respiratory tract infection
was substantially reduced in elderly patients when antibiotics had
been prescribed immediately (Petersen 2007). However, a likely
confounding factor in this study was the fact that sicker patients
and those more likely to suffer complications were offered imme-
diate antibiotics, introducing potential bias (Coenen 2007). The
trials that have been performed to date do not offer a clear way
to differentiate patients with acute bronchitis who might benefit
from antibiotic therapy from those who might not. In light of
this uncertainty, it is especially important for clinicians to share
the decision about whether to use antibiotics or not with their
patients, using the expected outcomes and their magnitude from
this review as a basis for their discussion.
In terms of interventions designed to reduce unnecessary antibi-
otic prescribing, some organisational and educational strategies
have been shown to be helpful. Use of delayed or deferred an-
tibiotic when patients consult with symptoms of acute bronchitis
is of some value (Dowell 2001). In a randomised trial in 22 UK
practices, 191 patients were randomised to either immediate or
delayed antibiotic (prescription lodged at the family practice re-
ception and patients were invited to collect it after one week, if
required). Over half (55%) in the delayed arm did not pick up
their prescriptions, though compared to the immediate arm pa-
tients, they were less satisfied with this strategy (Dowell 2001). In
a randomised trial of a patient information leaflet in 212 patients
with acute bronchitis for whom antibiotics were judged to be un-
necessary by their family doctor, the leaflet reduced uptake com-
pared to those without any information (49% versus 63%, risk
ratio 0.76) (Macfarlane 2002). This review contains a subgroup
from a more recent UK trial which tested the effectiveness of three
prescribing strategies and an information leaflet for acute lower
respiratory tract infections (Little 2005). The authors concluded
that no offer or a delayed offer of antibiotics for acute uncom-
plicated lower respiratory tract infection is acceptable and is asso-
ciated with little difference in symptom resolution. The authors
argue that the strategy of delayed or no prescribing is very likely to
reduce antibiotic use and beliefs in the effectiveness of antibiotics
for this condition. A recent review concluded that complex inter-
ventions that included education for physicians were most likely
to be effective in optimising antibiotic prescribing in primary care
settings (van der Velden 2012).
Implications for research
There is a widespread belief among clinicians and patients that
antibiotics provide effective treatment for acute bronchitis. There
is also widespread opinion among experts that antibiotic therapy is
unwarranted in this condition. The results of this review indicate
that there are, at most, limited benefits for some patients and this
must be placed in the context of the significant increase in adverse
events in the antibiotic group. However, it is also possible that any
apparent benefits from antibiotics are overestimated.
Ongoing research efforts should also be directed at the identifi-
cation of subsets of patients who are most likely or least likely
to benefit from antibiotic treatment (Coenen 2007; Little 2013).
Patient age, duration and severity of illness, chest examination
findings, sputum Gram stains, C-reactive protein levels (Jonsson
1997) and cigarette smoking are variables whichmay be important
in differentiation of these patient subsets. The ongoing GRACE
programme (genomics to combat resistance against antibiotics in
community-acquired lower respiratory tract infections in Europe,
http://www.grace-lrti.org) may provide answers to some of these
questions (Coenen 2007). Given the controversy around the term
’acute bronchitis’ it will also be important for researchers to be
very clear on their inclusion criteria to allow comparison across
studies. Finally, given the small impact, at best, of antibiotics on
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patient symptoms, investigators should continue the search for
other effective means of relieving themost troublesome symptoms
for patients suffering from acute bronchitis.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Brickfield 1986
Methods Double-blinded RCT
Participants 52 adults (aged 18 to 65), with 2 weeks or less of lower respiratory infection with sputum
production and no evidence of pneumonia clinically or radiographically. Drop-outs = 2/
52
Interventions Enteric-coated erythromycin 333 mg TID for 7 days versus placebo. Volunteers kept
daily logs of multiple symptoms and were re-examined on day 8
Outcomes Cough, sputum, fever, rhinorrhoea, chest discomfort, earache, sore throat, work disabil-
ity, feeling ill and nausea daily; and clinical impression at follow-up
Notes 29 volunteers had sputumcultured (27= normal flora, 1 =H. influenza, 1 = S. pneumonia)
, outcomes not reported; 17/23 had more than 5 white blood cells (wbc) on Gram stain.
Fewer than 30% of eligible patients opted to volunteer (most wanted antibiotics)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not reported
Allocation concealment (selection bias) Low risk
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk Not reported
Incomplete outcome data (attrition bias)
All outcomes
Low risk
Selective reporting (reporting bias) Unclear risk Not reported
Other bias Low risk
Dunlay 1987
Methods Double-blinded RCT
Participants 63 adults (age 18 or older) with productive cough (mean duration = 7 days) and no
clinical evidence of sinusitis or pneumonia. Drop-outs = 15 (6 - no follow-up at all;
9 - stopped taking pills during trial, authors state that no difference in results with or
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Dunlay 1987 (Continued)
without the partial data from the latter 9)
Interventions Enteric-coated erythromycin base, 333 mg TID for 10 days, versus placebo. Volunteers
kept daily logs of 5 symptoms and had follow-up visit at approximately day 14
Outcomes Day cough, night cough, sputum production, congestion, sore throat, feeling poor,
activity limitation and use of cough/cold medications daily; and cough, sputum and
abnormal lung examination at follow-up
Notes Only 20% of eligible patients enrolled in study (but unenrolled not different clinically
per chart review). 13 erythromycin volunteers dropped out due to gastrointestinal (GI)
side effects
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk
Allocation concealment (selection bias) Low risk
Blinding (performance bias and detection
bias)
All outcomes
Low risk
Blinding (performance bias and detection
bias)
Low risk
Incomplete outcome data (attrition bias)
All outcomes
Low risk
Selective reporting (reporting bias) Unclear risk Not reported
Other bias Low risk
Evans 2002
Methods Double-blinded RCT
Participants 220 adults (aged 18 to 88) with cough (with or without sputum) of 2 to 14 days duration
Interventions Azithromycin 500 mg on day 1 and 250 mg daily on days 2 to 5 versus vitamin C 500
mg on day 1 and 250 mg daily on days 2 to 5 (total dose 1.5 G)
Outcomes Acute bronchitis health-related quality of life on day 3 and 7, proportion of participants
who had returned to usual daily activities on days 3 and 7, side effects on days 3 and 7
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Evans 2002 (Continued)
Notes 88% of eligible population included. Both groups received cough suppressant (dex-
tromethorphan) and albuterol inhaler. No difference between groups in the use of al-
buterol inhaler at follow-up. 31/220 (14%) lost to follow-up. Timing of outcome at day
3 and day 7 (day 7 taken as outcome time in this review). Study was stopped by data-
monitoring and safety committee because “outcomes were equivalent and there was suf-
ficient precision to be confident that the likelihood of detecting a clinically meaningful
difference with a larger sample was so small that continued enrolment of patients would
be inappropriate”
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk
Allocation concealment (selection bias) Low risk
Blinding (performance bias and detection
bias)
All outcomes
Low risk
Blinding (performance bias and detection
bias)
Low risk
Incomplete outcome data (attrition bias)
All outcomes
Low risk
Selective reporting (reporting bias) Unclear risk Not reported
Other bias Low risk
Franks 1984
Methods Double-blinded RCT
Participants 67 patients aged 14 or older with less than 15 days of productive cough (in the absence of
clinical pneumonitis). Excluded if could not produce sputum specimen for Gram stain.
Drop-outs = 13/67
Interventions Trimethoprim-sulfamethoxazole (160/800) BID for 7 days versus identical appearing
placebo. Patients kept daily symptom logs. No follow-up visit
Outcomes Cough, night cough, sputum production, general well-being, fever, work disability, use
of adjunctive medications and side effects
Notes No mention of per cent of eligible patients who refused enrolment
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Franks 1984 (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not reported
Allocation concealment (selection bias) Low risk
Blinding (performance bias and detection
bias)
All outcomes
Low risk
Blinding (performance bias and detection
bias)
Low risk
Incomplete outcome data (attrition bias)
All outcomes
Low risk
Selective reporting (reporting bias) Unclear risk Not reported
Other bias Low risk
Howie 1970
Methods Double-blinded RCT
Participants 164 patients with a productive cough in conjunction with a cold or influenza-like illness
that was not resolving after 2 days
Interventions Self-treatment with demethyl chlortetracycline (300 mg) or placebo BID for 5 days.
Patients kept daily symptom logs. No initial or follow-up visits
Outcomes Duration of and presence on day 5 of cough, productive cough and purulent sputum;
and duration of time off work
Notes This was unpublished data about a subgroup of people with a cold or influenza-like
illness; total number of people who treated themselves for a single episode of illness and
returned symptom cards = 301
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not reported
Allocation concealment (selection bias) Low risk
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Howie 1970 (Continued)
Blinding (performance bias and detection
bias)
All outcomes
Low risk
Blinding (performance bias and detection
bias)
Low risk
Incomplete outcome data (attrition bias)
All outcomes
Low risk
Selective reporting (reporting bias) Unclear risk Not reported
Other bias Low risk
Hueston 1994
Methods Double-blinded RCT
Participants 23 adults (aged 18 to 65 years), with productive cough of less than 30 days duration and
no clinical evidence of pneumonia. Drop-outs = 0
Interventions Erythromycin (250 mg) QID for 10 days versus identical-looking placebo. Patients kept
daily symptom log and were re-examined on day 7 or 8
Outcomes Cough, night cough, ability to perform normal work and general well-being daily and
at follow-up; overall use of over-the-counter medications and side effects; and abnormal
lung exam at follow-up
Notes This was part of a 2 x 2 designed study comparing erythromycin + albuterol inhaler versus
erythromycin + placebo versus albuterol inhaler + placebo versus placebo + placebo.
The data extracted for this review were unpublished and limited to the erythromycin +
placebo group versus the placebo + placebo group
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not reported
Allocation concealment (selection bias) Unclear risk Not reported
Blinding (performance bias and detection
bias)
All outcomes
Low risk
Blinding (performance bias and detection
bias)
Unclear risk Not reported
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Hueston 1994 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Low risk
Selective reporting (reporting bias) Unclear risk Not reported
Other bias Unclear risk Not reported
Kaiser 1996
Methods Double-blinded RCT
Participants 75 patients (aged 16 to 64) with common cold and concomitant non-purulent tracheo-
bronchitis and no evidence of sinusitis, pharyngitis, purulent bronchitis or pneumonia.
Mean duration of illness 3 days
Interventions Amoxicillin-clavulanic acid (375 mg TID for 5 days) versus identical-looking placebo.
Patients re-evaluated on days 5 to 7
Outcomes Persistent or worse symptoms versus cure at follow-up
Notes These were unpublished data about a subgroup of patients in a study of patients with
common cold; total number of patients in study was 307
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not reported
Allocation concealment (selection bias) Low risk
Blinding (performance bias and detection
bias)
All outcomes
Low risk
Blinding (performance bias and detection
bias)
Low risk
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Not reported
Selective reporting (reporting bias) Unclear risk Not reported
Other bias Low risk
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King 1996
Methods Double-blinded RCT
Participants 91 patients (age 8 or older) with cough and sputum for up to 2 weeks, and no signs
of sinusitis, otitis or pneumonia and no localised abnormal lung exam. All tested for
Mycoplasma (one-half with negative serology excluded)
Interventions Erythromycin (250 mg QID for 10 days) versus identical-looking placebo. Volunteers
kept daily logs and returned for follow-up visit at day 14 to 18
Outcomes Cough, chest congestion, use of cough medication, general well-being, sleep and normal
activities
Notes No mention of eligible patients who refused to volunteer
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk
Allocation concealment (selection bias) Low risk
Blinding (performance bias and detection
bias)
All outcomes
Low risk
Blinding (performance bias and detection
bias)
Low risk
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Not reported
Selective reporting (reporting bias) Unclear risk Not reported
Other bias High risk
Little 2005
Methods RCT
Participants 426, subgroupof 807patientswith acute uncomplicated lower respiratory tract infection.
Inclusion criteria: aged 3 or more with uncomplicated LRTI for less than 21 days with
cough as main symptom and at least 1 of sputum, chest pain, dyspnoea and wheeze
Interventions 6-arm RCT: (1) no leaflet or antibiotic; (2) immediate antibiotics plus leaflet; (3) imme-
diate antibiotics and no leaflet; (4) leaflet only; (5) leaflet and delayed antibiotic; (6) no
leaflet and delayed antibiotics. Only data from the no treatment and immediate antibi-
otic groups included in the analysis. The antibiotic used was amoxicillin 250 mg TDS
26Antibiotics for acute bronchitis (Review)
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Little 2005 (Continued)
for 10 days (125 mg if less than 10 years) or erythromycin 250 mg QDS if penicillin
allergic
Outcomes Daily diary for 3 weeks recording antipyretic use and 6 symptoms (cough dyspnoea,
sputum production, well-being, sleep disturbance and activity disturbance); satisfaction
questionnaire; belief in antibiotics scale; reported antibiotic use; note review for re-
consultation
Notes 25% lost to follow-up in no treatment and immediate antibiotic arms
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk
Allocation concealment (selection bias) Low risk
Blinding (performance bias and detection
bias)
All outcomes
High risk Open design
Blinding (performance bias and detection
bias)
High risk
Incomplete outcome data (attrition bias)
All outcomes
Low risk
Selective reporting (reporting bias) Unclear risk Not reported
Other bias Low risk
Little 2013
Methods RCT
Participants 2061 patients aged 18 or over presenting with lower respiratory tract infection with
cough duration less than 28 days
Interventions Amoxicillin 1g 3 times daily for 7 days
Outcomes Duration of symptoms rated as moderately bad or worsening; mean symptom severity on
days 2 to 4; proportion with symptoms resolved on day 7; new or worsening symptoms
presenting clinically to GPs and adverse effects
Notes Adequately powered for subgroup analysis of patients aged over 60 (n = 595)
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Little 2013 (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk
Allocation concealment (selection bias) Low risk
Blinding (performance bias and detection
bias)
All outcomes
Low risk Clinicians, patients and outcome assessors all blinded
Blinding (performance bias and detection
bias)
Low risk
Incomplete outcome data (attrition bias)
All outcomes
Low risk 88% follow-up in both intervention and control groups
Selective reporting (reporting bias) Low risk
Other bias Low risk
Llor 2013
Methods RCT (3 arms)
Participants 420 patients age 18 to 70 years presenting with respiratory tract infection of 1 week
evolutionwith cough as the predominant symptom.We included data from the antibiotic
arm (137 patients) and the placebo arm (143 patients)
Interventions Ibuprofen or co-amoxiclav (dose 500 mg/125 mg)
Outcomes Number days with frequent cough defined using a symptom diary. Secondary outcomes
included clinically improved or cured, time to symptom resolution, median days with
cough and adverse effects
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Patients were randomised using a random number table into 3
blocks
Allocation concealment (selection bias) Low risk Patients were unaware of allocation and clinicians gave patients
sealed containers so also unaware of allocation
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Llor 2013 (Continued)
Blinding (performance bias and detection
bias)
All outcomes
Low risk Patients blinded and described as single-blind study. Tablets
placed in sealed containers before dispatch by an independent
pharmacist
Blinding (performance bias and detection
bias)
Low risk Outcomes collected in symptom diaries not seen by the investi-
gators
Incomplete outcome data (attrition bias)
All outcomes
Low risk > 90% follow-up
Selective reporting (reporting bias) Low risk Protocol available
Other bias Unclear risk Not reported
Matthys 2000
Methods Double-blinded RCT
Participants 294, a subgroup of 676 patients, mean age 39 (range 18 to 79 with acute bronchitis.
Inclusion criteria: aged 18 years or older, symptoms of recent onset within last 5 days,
nightly cough as main symptom (without at least 4 awakenings during the night) and
without reduced FEV1 (more than 75% normal)
Interventions 4-arm RCT: (1) myrtol standardised (phytotherapeutic extract); (2) cefuroxime 500 mg
BID; (3) ambroxol (mucolytic agent); (4) placebo capsules. Only data from cefuroxime
and placebo arms included in the analysis
Outcomes Daytime cough, night-time cough, type of cough and general well-being recorded by
each participant; clinical examination at follow-up; “overall efficacy” judge by physician
and participant; bronchial hyperreactivity; change in lung function; number of patients
with relapse within 4 weeks; side effects. Physician assessment at 7 and 14 days; diary
data on 3 follow-up time periods: day 7, 14, 15 to 28
Notes Secretolytics, mucolytics and antitussives prohibited during the study. Multiple hypoth-
esis testing for all 4 treatment groups. 3/343 (0.9%) lost to follow-up
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not reported
Allocation concealment (selection bias) Unclear risk Not reported
Blinding (performance bias and detection
bias)
Low risk
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Matthys 2000 (Continued)
All outcomes
Blinding (performance bias and detection
bias)
Unclear risk Not reported
Incomplete outcome data (attrition bias)
All outcomes
Low risk
Selective reporting (reporting bias) Unclear risk Not reported
Other bias Low risk
Nduba 2008
Methods Triple-blind, placebo-controlled RCT
Participants 529 of 660 patients, mean age 31; 55% female. Productive cough for < 2weeks, no serious
medical co-morbidity and no antibiotic treatment in previous 2 weeks. All patients had
HIV test and CXR at baseline. Excluded if CXR showed pneumonia or TB
Interventions Amoxicillin 500 mg TDS for 7 days versus identical placebo tablet
Outcomes Clinical cure at 14 days as measured by > 75% reduction in Acute Bronchitis Severity
Score
Notes Reported as first study of acute bronchitis treatment that used an equivalence design.
Data available for HIV-positive patients but not included in the review
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk The patients were randomised independently
using a random number generator
Allocation concealment (selection bias) Low risk Antibiotic or placebo tablets identical in ap-
pearance, taste and smell were place in identical
sealed opaque containers identifiable only with
a unique study identifier
Blinding (performance bias and detection
bias)
All outcomes
Low risk All clinical and research staff were blinded to
the allocation of participants and the allocation
schedule was kept in the office of the Chief
Research Pharmacist in the host institution
Blinding (performance bias and detection
bias)
Low risk
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Nduba 2008 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Low risk > 85% follow-up for outcome data
Selective reporting (reporting bias) Unclear risk No access to original protocol though selective
reporting not apparent from trial description
Other bias Low risk
Scherl 1987
Methods Double-blinded RCT
Participants 39 patients (older than 12 years old) with chief complaint of cough with purulent
sputum andwithout: other knownbacterial infection, flu-like syndrome, chief complaint
of coryza or sore throat with minimal sputum, or chest radiograph consistent with
pneumonia (not all had radiographs). Drop-outs = 8/31
Interventions Doxycycline (100 mg BID on day 1 and 100 mg QID on days 2 to 7) versus placebo.
Kept daily symptom log and had follow-up visit at day 14
Outcomes Cough, sputum, feverishness, days missed from work or normal activity, chest pain,
dyspnoea, side effects
Notes No mention of eligible patients who refused to volunteer
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not reported
Allocation concealment (selection bias) Low risk
Blinding (performance bias and detection
bias)
All outcomes
Low risk
Blinding (performance bias and detection
bias)
Low risk
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Not reported
Selective reporting (reporting bias) Unclear risk Not reported
Other bias Low risk
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Stott 1976
Methods Double-blinded RCT
Participants 212 patients aged > 14 years with cough and purulent sputum of up to 1 week. Excluded
if chest exam was abnormal. Drop-outs = 5/212
Interventions Patients given doxycycline or placebo (2 pills on day 1, then 1 daily for 9 days). Had
follow-up after 1 week, if “satisfied with outcome” then treatment ended; if not, then
completed remaining pills and continued to record symptoms. Volunteers completed
daily symptom logs
Outcomes Day cough, night cough, “yellow spit”, “clear spit”, “off color”, runny nose, sore throat,
general aches, headache, vomiting, off work daily and at follow-up; clinical impression
at follow-up; and illnesses over next 6 months
Notes No difference in average pill consumption between groups (9.3 in doxycycline group
versus 9.2 in placebo group). No mention of eligible patients who refused to volunteer
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not reported
Allocation concealment (selection bias) Low risk
Blinding (performance bias and detection
bias)
All outcomes
Low risk
Blinding (performance bias and detection
bias)
Unclear risk Not reported
Incomplete outcome data (attrition bias)
All outcomes
Low risk
Selective reporting (reporting bias) Unclear risk Not reported
Other bias Low risk
Verheij 1994
Methods Double-blinded RCT
Participants 158 adults (age 18 or older) with cough and purulent sputum, and no clinical sinusitis
or pneumonia. Drop-outs = 13/158
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Verheij 1994 (Continued)
Interventions Doxycycline (200 mg on day 1 and 100 mg on days 2 to 10) versus placebo. Volunteers
kept daily symptom log, and had follow-up visit on day 11
Outcomes Day cough, night cough, productive cough, feeling ill, impairment of activities and side
effects daily; and clinical impression and auscultatory abnormalities at follow-up
Notes 158/209 eligible patients entered study (no difference in age, sex or main symptoms
between volunteers and unenrolled)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not reported
Allocation concealment (selection bias) Low risk
Blinding (performance bias and detection
bias)
All outcomes
Low risk
Blinding (performance bias and detection
bias)
Low risk
Incomplete outcome data (attrition bias)
All outcomes
Low risk
Selective reporting (reporting bias) Unclear risk Not reported
Other bias Low risk
Williamson 1984
Methods Double-blinded RCT
Participants 74 adults (age 21 to 65) with cough and sputum, and concurrent upper respiratory tract
infection, rhonchi, or history of fever; excluded for temperature more than 39.5, signs
or symptoms of sinus infection, or chest radiograph with consolidation (but not ordered
on all). Drop-outs = 5/74
Interventions Doxycycline (100 mg BID on day 1, then 100 mg QID on days 2 to 7) versus identical-
looking placebo. Kept daily symptom log, returned for follow-up visit on day 7 to 10.
If not improved at follow-up, could get antibiotic prescription
Outcomes General well-being, bother of cough, night cough, activity limitation, feverishness, spu-
tum colour daily, doses of antitussives and clinical impression at follow-up
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Williamson 1984 (Continued)
Notes No mention of eligible patients who refused to volunteer
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk
Allocation concealment (selection bias) Low risk
Blinding (performance bias and detection
bias)
All outcomes
Low risk
Blinding (performance bias and detection
bias)
Low risk
Incomplete outcome data (attrition bias)
All outcomes
Low risk
Selective reporting (reporting bias) Unclear risk Not reported
Other bias Unclear risk Not reported
BID: twice a day
CXR: chest X-ray
FEV1: forced expiratory volume in one second
LRTI: lower respiratory tract infection
QID: four times a day
QDS: four times a day
RCT: randomised controlled trial
TB: tuberculosis
TDS: three times a day
TID: three times a day
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Bateiha 2002 185 patients with acute respiratory tract infection from 2 health centres in Jordan. Assignment to antibiotic
(azithromycin) was by means of alternation, not randomisation. At follow-up of 3 days, 1 week and 2 weeks,
patients administered azithromycin or placebo did similarly in terms of the proportions improved or cured and
in terms of duration of illness. The authors of the study conclude that routine use of antibiotics (azithromycin)
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(Continued)
in acute respiratory tract infection is unlikely to alter the course of the illness
Christ-Crain 2004 RCT concerned with application of a diagnostic test (serum calcitonin precursor, procalcitonin) which is raised
in bacterial infections. 243 patients admitted to hospital with suspected lower respiratory tract infections were
randomly assigned standard care (standard group; n = 119) or procalcitonin-guided treatment (procalcitonin
group; n = 124). On the basis of serum procalcitonin concentrations, use of antibiotics was more or less
discouraged (<0.1µG/Lor <0.25µG/L) or encouraged (greater thanor equal to 0.5 µG/Lor greater thanor equal
to 0.25 µG/L), respectively. Re-evaluation was possible after 6 to 24 hours in both groups. Primary endpoint was
use of antibiotics. 59 (24%) has diagnosis of “acute bronchitis”. Antibiotic use decreased in the procalcitonin
group. Withholding antibiotic treatment based on procalcitonin measurement did not compromise patient
outcome
Dowell 2001 RCT of “delayed” versus “immediate” antibiotics for acute cough. Patients randomised to “delayed” arm were
asked to wait a week before collecting their prescription. 55% of patients did not pick up their prescription.
More patients were satisfied and “enabled” in the immediate treatment arm
Gordon 1974 Participants were children with “symptoms referable to the respiratory tract”, therefore likely many had upper
respiratory infections (78% to 96% had runny nose, 74% to 83% had inflamed nasal mucosa)
Gottfarb 1994 Post-randomisation exclusion of 23% of the sample because of laboratory evidence of pertussis infection.
Outcomes not clearly reported. Inclusion criterion was cough, but not sputum production (therefore not
consistent with definition used in the other studies). Age of participants in this study was 7 months to 7 years:
the minimum age in the other studies was 8 (King 1996), 12 (Scherl 1987), or 14 or older (remaining studies)
Stephenson 1989 Participants were adults with upper respiratory infection. Not all had cough, and no information available on
the subgroup of patients with productive cough
Thomas 1978 Explicit data from the study were not published and the data are no longer available
RCT: randomised controlled trial
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D A T A A N D A N A L Y S E S
Comparison 1. Cough at follow-up visit
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Number of patients with cough 4 275 Risk Ratio (M-H, Fixed, 95% CI) 0.64 [0.49, 0.85]
Comparison 2. Night cough at follow-up visit
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Number of patients with night
cough
4 538 Risk Ratio (M-H, Fixed, 95% CI) 0.67 [0.54, 0.83]
Comparison 3. Productive cough at follow-up visit
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Number of patients with
productive cough
7 713 Risk Ratio (M-H, Fixed, 95% CI) 0.97 [0.82, 1.16]
1.1 Acute bronchitis studies 6 549 Risk Ratio (M-H, Fixed, 95% CI) 0.88 [0.72, 1.08]
1.2 Subgroup with productive
cough from URTI study
1 164 Risk Ratio (M-H, Fixed, 95% CI) 1.24 [0.88, 1.75]
Comparison 4. Days of cough
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Mean number of days of cough 7 2776 Mean Difference (IV, Fixed, 95% CI) -0.46 [-0.87, -0.04]
1.1 Acute bronchitis studies 6 2350 Mean Difference (IV, Fixed, 95% CI) -0.55 [1.00, -0.10]
1.2 Subgroup with no placebo
control
1 426 Mean Difference (IV, Fixed, 95% CI) 0.11 [-1.01, 1.23]
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Comparison 5. Days of productive cough
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Mean number of days of
productive cough
6 699 Mean Difference (IV, Fixed, 95% CI) -0.43 [-0.93, 0.07]
1.1 Acute bronchitis studies 5 535 Mean Difference (IV, Fixed, 95% CI) -0.52 [-1.03, -0.01]
1.2 Subgroup with productive
cough from URTI study
1 164 Mean Difference (IV, Fixed, 95% CI) 1.04 [-1.04, 3.12]
Comparison 6. Clinically improved
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Number of patients reporting no
activity limitations or described
as cured/globally improved
11 3841 Risk Ratio (M-H, Random, 95% CI) 1.07 [0.99, 1.15]
Comparison 7. Limitation in work or activities at follow-up visit
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Number of patients with
limitations
5 478 Risk Ratio (M-H, Fixed, 95% CI) 0.75 [0.46, 1.22]
Comparison 8. Days of feeling ill
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Mean number of days of feeling
ill
5 809 Mean Difference (IV, Fixed, 95% CI) -0.64 [-1.16, -0.13]
1.1 Acute bronchitis studies 4 435 Mean Difference (IV, Fixed, 95% CI) -0.58 [-1.16, -0.00]
1.2 Subgroup with no placebo
control
1 374 Mean Difference (IV, Fixed, 95% CI) -0.86 [-1.97, 0.25]
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Comparison 9. Days of impaired activities
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Mean number of days of
impaired activities
6 767 Mean Difference (IV, Fixed, 95% CI) -0.49 [-0.94, -0.04]
1.1 Acute bronchitis studies 5 393 Mean Difference (IV, Fixed, 95% CI) -0.48 [-0.96, 0.01]
1.2 Subgroup with no placebo
control
1 374 Mean Difference (IV, Fixed, 95% CI) -0.57 [-1.75, 0.61]
Comparison 10. Not improved by physician’s global assessment at follow-up visit
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Number of patients not
improved
6 891 Risk Ratio (M-H, Fixed, 95% CI) 0.61 [0.48, 0.79]
1.1 Acute bronchitis studies 5 816 Risk Ratio (M-H, Fixed, 95% CI) 0.44 [0.30, 0.65]
1.2 Subgroup with
non-purulent tracheobronchitis
from URTI study
1 75 Risk Ratio (M-H, Fixed, 95% CI) 1.03 [0.82, 1.29]
Comparison 11. Abnormal lung exam at follow-up visit
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Number of patients with
abnormal lung exams
5 613 Risk Ratio (M-H, Fixed, 95% CI) 0.54 [0.41, 0.70]
Comparison 12. Adverse effects
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Number of patients with adverse
effects
12 3496 Risk Ratio (M-H, Fixed, 95% CI) 1.20 [1.05, 1.36]
1.1 Acute bronchitis studies 11 3162 Risk Ratio (M-H, Fixed, 95% CI) 1.22 [1.07, 1.40]
1.2 Subgroup with no placebo
control
1 334 Risk Ratio (M-H, Fixed, 95% CI) 0.95 [0.61, 1.50]
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Analysis 1.1. Comparison 1 Cough at follow-up visit, Outcome 1 Number of patients with cough.
Review: Antibiotics for acute bronchitis
Comparison: 1 Cough at follow-up visit
Outcome: 1 Number of patients with cough
Study or subgroup Antibiotic Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Dunlay 1987 14/23 18/22 26.4 % 0.74 [ 0.51, 1.09 ]
Hueston 1994 8/11 6/9 9.5 % 1.09 [ 0.61, 1.96 ]
Verheij 1994 15/70 26/67 38.1 % 0.55 [ 0.32, 0.95 ]
Williamson 1984 10/39 17/34 26.0 % 0.51 [ 0.27, 0.96 ]
Total (95% CI) 143 132 100.0 % 0.64 [ 0.49, 0.85 ]
Total events: 47 (Antibiotic), 67 (Placebo)
Heterogeneity: Chi2 = 4.47, df = 3 (P = 0.22); I2 =33%
Test for overall effect: Z = 3.16 (P = 0.0016)
Test for subgroup differences: Not applicable
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Analysis 2.1. Comparison 2 Night cough at follow-up visit, Outcome 1 Number of patients with night cough.
Review: Antibiotics for acute bronchitis
Comparison: 2 Night cough at follow-up visit
Outcome: 1 Number of patients with night cough
Study or subgroup Antibiotic Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Dunlay 1987 7/21 14/24 11.0 % 0.57 [ 0.29, 1.14 ]
Hueston 1994 2/10 2/8 1.9 % 0.80 [ 0.14, 4.49 ]
Matthys 2000 63/171 96/169 81.1 % 0.65 [ 0.51, 0.82 ]
Verheij 1994 8/69 7/66 6.0 % 1.09 [ 0.42, 2.85 ]
Total (95% CI) 271 267 100.0 % 0.67 [ 0.54, 0.83 ]
Total events: 80 (Antibiotic), 119 (Placebo)
Heterogeneity: Chi2 = 1.32, df = 3 (P = 0.72); I2 =0.0%
Test for overall effect: Z = 3.62 (P = 0.00030)
Test for subgroup differences: Not applicable
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Analysis 3.1. Comparison 3 Productive cough at follow-up visit, Outcome 1 Number of patients with
productive cough.
Review: Antibiotics for acute bronchitis
Comparison: 3 Productive cough at follow-up visit
Outcome: 1 Number of patients with productive cough
Study or subgroup Antibiotic Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Acute bronchitis studies
Dunlay 1987 13/23 14/22 10.7 % 0.89 [ 0.55, 1.43 ]
Hueston 1994 9/11 6/9 4.9 % 1.23 [ 0.72, 2.10 ]
King 1996 28/41 27/31 23.0 % 0.78 [ 0.61, 1.01 ]
Stott 1976 30/104 32/103 24.0 % 0.93 [ 0.61, 1.41 ]
Verheij 1994 13/69 14/67 10.6 % 0.90 [ 0.46, 1.77 ]
Williamson 1984 2/37 3/32 2.4 % 0.58 [ 0.10, 3.24 ]
Subtotal (95% CI) 285 264 75.6 % 0.88 [ 0.72, 1.08 ]
Total events: 95 (Antibiotic), 96 (Placebo)
Heterogeneity: Chi2 = 2.60, df = 5 (P = 0.76); I2 =0.0%
Test for overall effect: Z = 1.20 (P = 0.23)
2 Subgroup with productive cough from URTI study
Howie 1970 40/81 33/83 24.4 % 1.24 [ 0.88, 1.75 ]
Subtotal (95% CI) 81 83 24.4 % 1.24 [ 0.88, 1.75 ]
Total events: 40 (Antibiotic), 33 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.23 (P = 0.22)
Total (95% CI) 366 347 100.0 % 0.97 [ 0.82, 1.16 ]
Total events: 135 (Antibiotic), 129 (Placebo)
Heterogeneity: Chi2 = 6.10, df = 6 (P = 0.41); I2 =2%
Test for overall effect: Z = 0.33 (P = 0.74)
Test for subgroup differences: Chi2 = 2.79, df = 1 (P = 0.09), I2 =64%
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Analysis 4.1. Comparison 4 Days of cough, Outcome 1 Mean number of days of cough.
Review: Antibiotics for acute bronchitis
Comparison: 4 Days of cough
Outcome: 1 Mean number of days of cough
Study or subgroup Antibiotic Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Acute bronchitis studies
King 1996 50 8.76 (7.57) 42 8.94 (10.37) 1.2 % -0.18 [ -3.95, 3.59 ]
Little 2013 908 8.81 (8) 899 9.3 (7.78) 33.0 % -0.49 [ -1.22, 0.24 ]
Scherl 1987 16 9.4 (3.08) 15 10.8 (2.38) 4.7 % -1.40 [ -3.33, 0.53 ]
Stott 1976 104 6.4 (2.6) 103 6.3 (3) 29.9 % 0.10 [ -0.67, 0.87 ]
Verheij 1994 71 4.7 (3.1) 69 6.2 (3.2) 16.0 % -1.50 [ -2.54, -0.46 ]
Williamson 1984 39 7.97 (7.22) 34 10.41 (8.8) 1.3 % -2.44 [ -6.17, 1.29 ]
Subtotal (95% CI) 1188 1162 86.2 % -0.55 [ -1.00, -0.10 ]
Heterogeneity: Chi2 = 7.75, df = 5 (P = 0.17); I2 =35%
Test for overall effect: Z = 2.38 (P = 0.017)
2 Subgroup with no placebo control
Little 2005 214 11.56 (6.04) 212 11.45 (5.8) 13.8 % 0.11 [ -1.01, 1.23 ]
Subtotal (95% CI) 214 212 13.8 % 0.11 [ -1.01, 1.23 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.19 (P = 0.85)
Total (95% CI) 1402 1374 100.0 % -0.46 [ -0.87, -0.04 ]
Heterogeneity: Chi2 = 8.88, df = 6 (P = 0.18); I2 =32%
Test for overall effect: Z = 2.14 (P = 0.033)
Test for subgroup differences: Chi2 = 1.13, df = 1 (P = 0.29), I2 =12%
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Analysis 5.1. Comparison 5 Days of productive cough, Outcome 1 Mean number of days of productive
cough.
Review: Antibiotics for acute bronchitis
Comparison: 5 Days of productive cough
Outcome: 1 Mean number of days of productive cough
Study or subgroup Antibiotic Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Acute bronchitis studies
King 1996 50 6.34 (6.74) 41 5.76 (5.97) 3.6 % 0.58 [ -2.03, 3.19 ]
Scherl 1987 16 8.5 (3.08) 15 10.4 (2.78) 5.8 % -1.90 [ -3.96, 0.16 ]
Stott 1976 100 4.7 (2.9) 102 5.3 (3.1) 36.3 % -0.60 [ -1.43, 0.23 ]
Verheij 1994 71 2.8 (2.4) 69 3.3 (3) 30.6 % -0.50 [ -1.40, 0.40 ]
Williamson 1984 39 2.03 (2.21) 32 2.19 (2.74) 18.0 % -0.16 [ -1.34, 1.02 ]
Subtotal (95% CI) 276 259 94.3 % -0.52 [ -1.03, -0.01 ]
Heterogeneity: Chi2 = 2.80, df = 4 (P = 0.59); I2 =0.0%
Test for overall effect: Z = 1.98 (P = 0.048)
2 Subgroup with productive cough from URTI study
Howie 1970 81 8.77 (6.75) 83 7.73 (6.84) 5.7 % 1.04 [ -1.04, 3.12 ]
Subtotal (95% CI) 81 83 5.7 % 1.04 [ -1.04, 3.12 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.98 (P = 0.33)
Total (95% CI) 357 342 100.0 % -0.43 [ -0.93, 0.07 ]
Heterogeneity: Chi2 = 4.83, df = 5 (P = 0.44); I2 =0.0%
Test for overall effect: Z = 1.69 (P = 0.091)
Test for subgroup differences: Chi2 = 2.03, df = 1 (P = 0.15), I2 =51%
-10 -5 0 5 10
Favours antibiotic Favours placebo
43Antibiotics for acute bronchitis (Review)
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 6.1. Comparison 6 Clinically improved, Outcome 1 Number of patients reporting no activity
limitations or described as cured/globally improved.
Review: Antibiotics for acute bronchitis
Comparison: 6 Clinically improved
Outcome: 1 Number of patients reporting no activity limitations or described as cured/globally improved
Study or subgroup Antibiotic Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Stott 1976 94/104 86/103 10.7 % 1.08 [ 0.97, 1.20 ]
Franks 1984 14/19 17/29 2.7 % 1.26 [ 0.84, 1.89 ]
Williamson 1984 35/37 31/32 11.0 % 0.98 [ 0.88, 1.08 ]
Brickfield 1986 21/26 14/24 2.9 % 1.38 [ 0.94, 2.04 ]
Dunlay 1987 19/20 20/23 7.3 % 1.09 [ 0.91, 1.32 ]
Verheij 1994 64/73 55/72 8.6 % 1.15 [ 0.98, 1.34 ]
Matthys 2000 158/171 136/172 11.5 % 1.17 [ 1.07, 1.28 ]
Evans 2002 86/97 82/92 10.9 % 0.99 [ 0.90, 1.10 ]
Nduba 2008 270/330 277/330 12.2 % 0.97 [ 0.91, 1.04 ]
Llor 2013 107/137 123/143 10.5 % 0.91 [ 0.81, 1.01 ]
Little 2013 539/908 436/899 11.6 % 1.22 [ 1.12, 1.33 ]
Total (95% CI) 1922 1919 100.0 % 1.07 [ 0.99, 1.15 ]
Total events: 1407 (Antibiotic), 1277 (Placebo)
Heterogeneity: Tau2 = 0.01; Chi2 = 42.49, df = 10 (P<0.00001); I2 =76%
Test for overall effect: Z = 1.77 (P = 0.077)
Test for subgroup differences: Not applicable
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Analysis 7.1. Comparison 7 Limitation in work or activities at follow-up visit, Outcome 1 Number of
patients with limitations.
Review: Antibiotics for acute bronchitis
Comparison: 7 Limitation in work or activities at follow-up visit
Outcome: 1 Number of patients with limitations
Study or subgroup Antibiotic Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Dunlay 1987 1/20 3/23 8.8 % 0.38 [ 0.04, 3.40 ]
Evans 2002 11/97 10/92 32.4 % 1.04 [ 0.47, 2.34 ]
Franks 1984 5/19 12/29 30.0 % 0.64 [ 0.27, 1.52 ]
Verheij 1994 6/67 9/65 28.8 % 0.65 [ 0.24, 1.71 ]
Williamson 1984 0/36 0/30 Not estimable
Total (95% CI) 239 239 100.0 % 0.75 [ 0.46, 1.22 ]
Total events: 23 (Antibiotic), 34 (Placebo)
Heterogeneity: Chi2 = 1.23, df = 3 (P = 0.75); I2 =0.0%
Test for overall effect: Z = 1.16 (P = 0.25)
Test for subgroup differences: Not applicable
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Analysis 8.1. Comparison 8 Days of feeling ill, Outcome 1 Mean number of days of feeling ill.
Review: Antibiotics for acute bronchitis
Comparison: 8 Days of feeling ill
Outcome: 1 Mean number of days of feeling ill
Study or subgroup Antibiotic Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Acute bronchitis studies
King 1996 25 3.92 (4.24) 27 3.67 (4.35) 4.9 % 0.25 [ -2.09, 2.59 ]
Stott 1976 84 3.8 (2.2) 91 4.4 (2.7) 50.1 % -0.60 [ -1.33, 0.13 ]
Verheij 1994 71 4.3 (3) 69 5.1 (3.5) 22.7 % -0.80 [ -1.88, 0.28 ]
Williamson 1984 37 20.1 (11.2) 31 18.5 (12.9) 0.8 % 1.60 [ -4.20, 7.40 ]
Subtotal (95% CI) 217 218 78.5 % -0.58 [ -1.16, 0.00 ]
Heterogeneity: Chi2 = 1.19, df = 3 (P = 0.76); I2 =0.0%
Test for overall effect: Z = 1.97 (P = 0.049)
2 Subgroup with no placebo control
Little 2005 194 8.12 (5.1) 180 8.98 (5.8) 21.5 % -0.86 [ -1.97, 0.25 ]
Subtotal (95% CI) 194 180 21.5 % -0.86 [ -1.97, 0.25 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.52 (P = 0.13)
Total (95% CI) 411 398 100.0 % -0.64 [ -1.16, -0.13 ]
Heterogeneity: Chi2 = 1.38, df = 4 (P = 0.85); I2 =0.0%
Test for overall effect: Z = 2.45 (P = 0.014)
Test for subgroup differences: Chi2 = 0.19, df = 1 (P = 0.66), I2 =0.0%
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Analysis 9.1. Comparison 9 Days of impaired activities, Outcome 1 Mean number of days of impaired
activities.
Review: Antibiotics for acute bronchitis
Comparison: 9 Days of impaired activities
Outcome: 1 Mean number of days of impaired activities
Study or subgroup Antibiotic Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Acute bronchitis studies
King 1996 36 0.75 (1.02) 32 2.16 (3.2) 15.0 % -1.41 [ -2.57, -0.25 ]
Scherl 1987 16 3.4 (2.46) 15 3.9 (1.59) 9.6 % -0.50 [ -1.95, 0.95 ]
Stott 1976 44 6.2 (2.8) 46 6.2 (3.1) 13.5 % 0.0 [ -1.22, 1.22 ]
Verheij 1994 71 1.6 (2.4) 69 2.5 (3.3) 21.9 % -0.90 [ -1.86, 0.06 ]
Williamson 1984 36 2.25 (1.67) 28 2.07 (1.88) 25.7 % 0.18 [ -0.70, 1.06 ]
Subtotal (95% CI) 203 190 85.7 % -0.48 [ -0.96, 0.01 ]
Heterogeneity: Chi2 = 5.95, df = 4 (P = 0.20); I2 =33%
Test for overall effect: Z = 1.94 (P = 0.053)
2 Subgroup with no placebo control
Little 2005 194 7.61 (5.67) 180 8.18 (5.99) 14.3 % -0.57 [ -1.75, 0.61 ]
Subtotal (95% CI) 194 180 14.3 % -0.57 [ -1.75, 0.61 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.94 (P = 0.35)
Total (95% CI) 397 370 100.0 % -0.49 [ -0.94, -0.04 ]
Heterogeneity: Chi2 = 5.97, df = 5 (P = 0.31); I2 =16%
Test for overall effect: Z = 2.15 (P = 0.032)
Test for subgroup differences: Chi2 = 0.02, df = 1 (P = 0.89), I2 =0.0%
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Analysis 10.1. Comparison 10 Not improved by physician’s global assessment at follow-up visit, Outcome 1
Number of patients not improved.
Review: Antibiotics for acute bronchitis
Comparison: 10 Not improved by physician’s global assessment at follow-up visit
Outcome: 1 Number of patients not improved
Study or subgroup Antibiotic Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Acute bronchitis studies
Brickfield 1986 5/26 10/24 10.3 % 0.46 [ 0.18, 1.16 ]
Matthys 2000 13/171 36/172 35.5 % 0.36 [ 0.20, 0.66 ]
Stott 1976 3/106 7/103 7.0 % 0.42 [ 0.11, 1.57 ]
Verheij 1994 9/73 17/72 16.9 % 0.52 [ 0.25, 1.09 ]
Williamson 1984 2/37 1/32 1.1 % 1.73 [ 0.16, 18.20 ]
Subtotal (95% CI) 413 403 70.7 % 0.44 [ 0.30, 0.65 ]
Total events: 32 (Antibiotic), 71 (Placebo)
Heterogeneity: Chi2 = 1.92, df = 4 (P = 0.75); I2 =0.0%
Test for overall effect: Z = 4.13 (P = 0.000036)
2 Subgroup with non-purulent tracheobronchitis from URTI study
Kaiser 1996 30/37 30/38 29.3 % 1.03 [ 0.82, 1.29 ]
Subtotal (95% CI) 37 38 29.3 % 1.03 [ 0.82, 1.29 ]
Total events: 30 (Antibiotic), 30 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.23 (P = 0.82)
Total (95% CI) 450 441 100.0 % 0.61 [ 0.48, 0.79 ]
Total events: 62 (Antibiotic), 101 (Placebo)
Heterogeneity: Chi2 = 24.59, df = 5 (P = 0.00017); I2 =80%
Test for overall effect: Z = 3.87 (P = 0.00011)
Test for subgroup differences: Chi2 = 13.57, df = 1 (P = 0.00), I2 =93%
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Favours antibiotic Favours placebo
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Analysis 11.1. Comparison 11 Abnormal lung exam at follow-up visit, Outcome 1 Number of patients with
abnormal lung exams.
Review: Antibiotics for acute bronchitis
Comparison: 11 Abnormal lung exam at follow-up visit
Outcome: 1 Number of patients with abnormal lung exams
Study or subgroup Antibiotic Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Dunlay 1987 0/23 6/22 6.2 % 0.07 [ 0.00, 1.24 ]
Hueston 1994 7/14 5/9 5.7 % 0.90 [ 0.41, 1.97 ]
Matthys 2000 46/171 83/172 77.8 % 0.56 [ 0.42, 0.75 ]
Verheij 1994 5/70 8/67 7.7 % 0.60 [ 0.21, 1.74 ]
Williamson 1984 0/36 2/29 2.6 % 0.16 [ 0.01, 3.25 ]
Total (95% CI) 314 299 100.0 % 0.54 [ 0.41, 0.70 ]
Total events: 58 (Antibiotic), 104 (Placebo)
Heterogeneity: Chi2 = 4.25, df = 4 (P = 0.37); I2 =6%
Test for overall effect: Z = 4.57 (P < 0.00001)
Test for subgroup differences: Not applicable
0.1 0.2 0.5 1 2 5 10
Favours antibiotic Favours placebo
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Analysis 12.1. Comparison 12 Adverse effects, Outcome 1 Number of patients with adverse effects.
Review: Antibiotics for acute bronchitis
Comparison: 12 Adverse effects
Outcome: 1 Number of patients with adverse effects
Study or subgroup Antibiotic Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Acute bronchitis studies
Brickfield 1986 5/26 9/24 2.8 % 0.51 [ 0.20, 1.32 ]
Dunlay 1987 4/31 0/26 0.2 % 7.59 [ 0.43, 134.80 ]
Evans 2002 24/97 19/92 5.9 % 1.20 [ 0.71, 2.04 ]
Franks 1984 3/25 1/29 0.3 % 3.48 [ 0.39, 31.38 ]
Hueston 1994 3/14 2/9 0.7 % 0.96 [ 0.20, 4.69 ]
King 1996 18/49 6/42 2.0 % 2.57 [ 1.12, 5.88 ]
Little 2013 249/867 206/860 62.9 % 1.20 [ 1.02, 1.41 ]
Llor 2013 10/124 4/136 1.2 % 2.74 [ 0.88, 8.52 ]
Matthys 2000 24/171 28/172 8.5 % 0.86 [ 0.52, 1.42 ]
Stott 1976 12/104 11/106 3.3 % 1.11 [ 0.51, 2.41 ]
Verheij 1994 15/78 9/80 2.7 % 1.71 [ 0.80, 3.67 ]
Subtotal (95% CI) 1586 1576 90.5 % 1.22 [ 1.07, 1.40 ]
Total events: 367 (Antibiotic), 295 (Placebo)
Heterogeneity: Chi2 = 13.55, df = 10 (P = 0.19); I2 =26%
Test for overall effect: Z = 2.95 (P = 0.0032)
2 Subgroup with no placebo control
Little 2005 34/187 28/147 9.5 % 0.95 [ 0.61, 1.50 ]
Subtotal (95% CI) 187 147 9.5 % 0.95 [ 0.61, 1.50 ]
Total events: 34 (Antibiotic), 28 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.20 (P = 0.84)
Total (95% CI) 1773 1723 100.0 % 1.20 [ 1.05, 1.36 ]
Total events: 401 (Antibiotic), 323 (Placebo)
Heterogeneity: Chi2 = 14.49, df = 11 (P = 0.21); I2 =24%
Test for overall effect: Z = 2.76 (P = 0.0058)
Test for subgroup differences: Chi2 = 1.07, df = 1 (P = 0.30), I2 =7%
0.1 0.2 0.5 1 2 5 10
Favours antibiotic Favours placebo
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A P P E N D I C E S
Appendix 1. MEDLINE (Ovid) and CENTRAL search strategy
1 exp Bronchitis/
2 bronchit*.tw.
3 (bronchial adj2 infect*).tw.
4 exp Respiratory Tract Infections/
5 or/1-4
6 exp Anti-Bacterial Agents/
7 exp Lactams/
8 exp Tetracyclines/
9 exp Aminoglycosides/
10 exp Glycopeptides/
11 exp Macrolides/
12 antibiotic*.tw.
13 (alamethicin or amdinocillin* or amikacin or amoxicillin* or ampicillin or aurodox or azithromycin or azlocillin or aztreonam or
bacitracin or bacteriocin* or brefeldin* or butirosin* or candicidin or carbenicillin or carfecillin or cefaclor or cefadroxil or cefamandole
or cefazolin or cefixime or cefmenoxime or cefmetazole or cefonicid or cefoperazone or cefotaxime or cefotetan or cefotiam or cefoxitin
or cefsulodin or ceftazidime or ceftizoxime or ceftriaxone or cefuroxime or cephacetrile or cephalexin or cephaloglycin or cephaloridine
or cephalosporin* or cephalothin or cephapirin or cephradine or chloramphenicol or chlortetracycline or citrinin or clarithromycin or
clavulanic acid* or clindamycin or cloxacillin or colistin or cyclacillin or dactinomycin or daptomycin or demeclocycline or dibekacin
or dicloxacillin or dihydrostreptomycin* or distamycin* or doxycycline or echinomycin or edeine or erythromycin* or floxacillin or
framycetin or fusidic acid or gentamicin* or gramicidin or imipenemor lactam* or lasalocid or leucomycins or lymecycline ormepartricin
or methacycline or methicillin or mezlocillin or mikamycin or minocycline or miocamycin or moxalactam or mupirocin or mycobacillin
or nafcillin or nebramycin or enigericin or nisin or novobiocin or nystatin or ofloxacin or oligomycins or oxacillin or oxytetracycline
or penicillanic acid or penicillic acid or penicillin* or piperacillin or pivampicillin or polymyxin* or pristinamycin* or prodigiosin or
rifabutin or ristocetin or rolitetracycline or roxarsone or rutamycin or sirolimus or sisomicin or spectinomycin or streptogramin* or
streptovaricin or sulbactam or sulbenicillin or talampicillin or teicoplanin or tetracycline or thiamphenicol or thiostrepton or ticarcillin
or tobramycin or troleandomycin or tylosin or tyrocidine or tyrothricin or valinomycin or vancomycin or vernamycin* or viomycin*
or virginiamycin* or beta-lactam*).tw,nm.
14 or/6-13
15 5 and 14
We combined the MEDLINE search with the Cochrane Highly Sensitive Strategy for identifying randomised trials in MEDLINE:
sensitivity- and precision-maximising version (2008 revision); Ovid format (Lefebvre 2011).
Appendix 2. Embase.com search strategy
#2.24 #2.15 AND #2.23
#2.23 #2.18 NOT #2.22
#2.22 #2.19 NOT #2.21
#2.21 #2.19 AND #2.20
#2.20 ’human’/de
#2.19 ’animal’/de OR ’nonhuman’/de OR ’animal experiment’/de
#2.18 #2.16 OR #2.17
#2.17 random*:ab,ti OR placebo*:ab,ti OR crossover*:ab,ti OR ’cross over’:ab,ti OR allocat*:ab,ti OR trial:ti OR (doubl* NEXT/1
blind*):ab,ti
#2.16 ’randomized controlled trial’/exp OR ’single blind procedure’/exp OR ’double blind procedure’/exp OR ’crossover procedure’/
exp
#2.15 #2.5 AND #2.14
#2.14 #2.6 OR #2.7 OR #2.8 OR #2.9 OR #2.10 OR #2.11 OR #2.12 OR #2.13
#2.13 alamethicin:ab,ti OR amdinocillin*:ab,ti OR amikacin:ab,ti OR amoxicillin*:ab,ti OR ampicillin:ab,ti OR aurodox:ab,ti OR
azithromycin:ab,ti OR azlocillin:ab,ti OR aztreonam:ab,ti OR bacitracin:ab,ti OR bacteriocin*:ab,ti OR brefeldin*:ab,ti OR butirosin*:
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ab,ti OR candicidin:ab,ti OR carbenicillin:ab,ti OR carfecillin:ab,ti OR cefaclor:ab,ti OR cefadroxil:ab,ti OR cefamandole:ab,ti OR
cefazolin:ab,tiOR cefixime:ab,tiOR cefmenoxime:ab,tiOR cefmetazole:ab,tiOR cefonicid:ab,tiOR cefoperazone:ab,tiOR cefotaxime:
ab,ti OR cefotetan:ab,ti OR cefotiam:ab,ti OR cefoxitin:ab,ti OR cefsulodin:ab,ti OR ceftazidime:ab,ti OR ceftizoxime:ab,ti OR
ceftriaxone:ab,ti OR
cefuroxime:ab,ti OR cephacetrile:ab,ti OR cephalexin:ab,ti OR cephaloglycin:ab,ti OR cephaloridine:ab,ti OR cephalosporin*:ab,ti
OR cephalothin:ab,ti OR cephapirin:ab,ti OR cephradine:ab,ti OR chloramphenicol:ab,ti OR chlortetracycline:ab,ti OR citrinin:ab,ti
OR clarithromycin:ab,ti OR ’clavulanic acid’:ab,ti OR clindamycin:ab,ti OR cloxacillin:ab,ti OR colistin:ab,ti OR cyclacillin:ab,ti OR
dactinomycin:ab,ti OR daptomycin:ab,ti OR
demeclocycline:ab,ti OR dibekacin:ab,ti OR dicloxacillin:ab,ti OR dihydrostreptomycin*:ab,ti OR distamycin*:ab,ti OR doxycycline:
ab,tiOR echinomycin:ab,tiOR edeine:ab,tiOR erythromycin*:ab,tiORfloxacillin:ab,tiOR framycetin:ab,tiOR ’fusidic acid’:ab,tiOR
gentamicin*:ab,ti OR gramicidin:ab,ti OR imipenem:ab,ti OR lactam*:ab,ti OR lasalocid:ab,ti OR leucomycins:ab,ti OR lymecycline:
ab,ti OR mepartricin:ab,ti OR methacycline:ab,ti OR
methicillin:ab,ti OR mezlocillin:ab,ti OR mikamycin:ab,ti OR minocycline:ab,ti OR miocamycin:ab,ti OR moxalactam:ab,ti OR
mupirocin:ab,ti OR mycobacillin:ab,ti OR nafcillin:ab,ti OR nebramycin:ab,ti OR enigericin:ab,ti OR nisin:ab,ti OR novobiocin:
ab,ti OR nystatin:ab,ti OR ofloxacin:ab,ti OR oligomycins:ab,ti OR oxacillin:ab,ti OR oxytetracycline:ab,ti OR ’penicillanic acid’:ab,ti
OR ’penicillic acid’:ab,ti OR penicillin*:ab,ti OR piperacillin:ab,ti OR pivampicillin:ab,ti OR polymyxin*:ab,ti OR pristinamycin*:
ab,ti OR prodigiosin:ab,ti OR rifabutin:ab,ti OR ristocetin:ab,ti OR rolitetracycline:ab,ti OR roxarsone:ab,ti OR rutamycin:ab,ti
OR sirolimus:ab,ti OR sisomicin:ab,ti OR spectinomycin:ab,ti OR streptogramin*:ab,ti OR streptovaricin:ab,ti OR sulbactam:ab,ti
OR sulbenicillin:ab,ti OR talampicillin:ab,ti OR teicoplanin:ab,ti OR tetracycline:ab,ti OR thiamphenicol:ab,ti OR thiostrepton:
ab,ti OR ticarcillin:ab,ti OR tobramycin:ab,ti OR troleandomycin:ab,ti OR tylosin:ab,ti OR tyrocidine:ab,ti OR tyrothricin:ab,ti OR
valinomycin:ab,ti OR vancomycin:ab,ti OR vernamycin*:ab,ti OR viomycin*:ab,ti OR virginiamycin*:ab,ti OR ’beta-lactam’:ab,ti OR
’beta-lactams’:ab,ti
#2.12 antibiotic*:ab,ti
#2.11 ’macrolide’/exp
#2.10 ’glycopeptide’/de
#2.9 ’aminoglycoside’/de
#2.8 ’tetracycline derivative’/exp
#2.7 ’lactam’/exp
#2.6 ’antibiotic agent’/de
#2.5 #2.1 OR #2.2 OR #2.3 OR #2.4
#2.4 ’respiratory tract infection’/de OR ’lower respiratory tract infection’/de
#2.3 (bronchial* NEAR/2 infect*):ab,ti
#2.2 bronchit*:ab,ti
#2.1 ’bronchitis’/exp
Appendix 3. LILACS (BIREME) search strategy
(mh:bronchitis OR bronchit* OR bronquitis OR bronquite OR mh:c08.127.446* OR mh:c08.381.495.146* OR mh:c08.730.099*
OR “bronchial infection” OR “bronchial infections” OR mh:“Respiratory Tract Infections” OR “respiratory tract infection” OR
“respiratory tract infections” OR “Infecciones del Sistema Respiratorio” OR “Infecções Respiratórias”) AND (mh:“Anti-Bacterial
Agents” OR antibiotic* OR antibacterianos OR mh:d27.505.954.122.085* OR mh:lactams OR lactam* OR mh:d02.065.589*
OR mh:d03.383.411* OR mh:tetracyclines OR tetracyclin* OR tetraciclinas OR mh:d02.455.426.559.847.562.900* OR mh:
d04.615.562.900* OR mh:aminoglycosides OR aminoglicósidos OR aminoglicosídeos OR mh:d09.408.051* OR aminoglycoside*
OR mh:glycopeptides OR glycopeptide* OR glicopéptidos OR glicopeptídeos OR mh:d09.400.420* OR mh:d12.644.233* OR mh:
macrolides OR macrolide* OR macrólidos OR macrolídeos OR mh:d02.540.505* OR alamethicin OR amdinocillin* OR amikacin
OR amoxicillin* OR ampicillin OR aurodox OR azithromycin OR azlocillin OR aztreonam OR bacitracin OR bacteriocin* OR
brefeldin* OR butirosin* OR candicidin OR carbenicillin OR carfecillinOR cefaclor OR cefadroxil OR cefamandole OR cefazolin OR
cefixime OR cefmenoxime OR cefmetazole OR cefonicid OR cefoperazone OR cefotaxime OR cefotetan OR cefotiam OR cefoxitin
OR cefsulodin OR ceftazidime OR ceftizoxime OR ceftriaxone OR cefuroxime OR cephacetrile OR cephalexin OR cephaloglycin
OR cephaloridine OR cephalosporin* OR cephalothin OR cephapirin OR cephradine OR chloramphenicol OR chlortetracycline
OR citrinin OR clarithromycin OR “clavulanic acid” OR clindamycin OR cloxacillin OR colistin OR cyclacillin OR dactinomycin
OR daptomycin OR demeclocycline OR dibekacin OR dicloxacillin OR dihydrostreptomycin* OR distamycin* OR doxycycline
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OR echinomycin OR edeine OR erythromycin* OR floxacillin OR framycetin OR “fusidic acid” OR gentamicin* OR gramicidin
OR imipenem OR lactam* OR lasalocid OR leucomycins OR lymecycline OR mepartricin OR methacycline OR methicillin OR
mezlocillin OR mikamycin OR minocycline OR miocamycin OR moxalactam OR mupirocin OR mycobacillin OR nafcillin OR
nebramycin OR enigericin OR nisin OR novobiocin OR nystatin OR ofloxacin OR oligomycins OR oxacillin OR oxytetracycline
OR “penicillanic acid” OR “penicillic acid” OR penicillin* OR piperacillin OR pivampicillin OR polymyxin* OR pristinamycin* OR
prodigiosin OR rifabutin OR ristocetin OR rolitetracycline OR roxarsone OR rutamycin OR sirolimus OR sisomicin OR spectino-
mycin OR streptogramin* OR streptovaricin OR sulbactam OR sulbenicillin OR talampicillin OR teicoplanin OR tetracycline OR
thiamphenicol OR thiostrepton OR ticarcillin OR tobramycin OR troleandomycin OR tylosin OR tyrocidine OR tyrothricin OR
valinomycin OR vancomycin OR vernamycin* OR viomycin* OR virginiamycin* OR “beta-lactam” OR “beta-lactams”) AND db:
(“LILACS”) AND type˙of˙study:(“clinical˙trials”)
Appendix 4. Previous search strategy
In this updated review, we searched the Cochrane Central Register of Controlled trials (CENTRAL) (The Cochrane Library 2007, issue
4), which includes the Acute Respiratory Infections (ARI) Group’s Specialised Register; MEDLINE (1966 to December 2007); and
EMBASE (1974 to December 2007). For details of the search strategy used, see Appendix 2.
The updated MEDLINE (OVID) search used the following search strategy:
1 RANDOMIZED CONTROLLED TRIAL.pt. (228029)
2 CONTROLLED CLINICAL TRIAL.pt. (73939)
3 RANDOMIZED CONTROLLED TRIALS.sh. (46488)
4 RANDOM ALLOCATION.sh. (56676)
5 DOUBLE BLIND METHOD.sh. (89072)
6 SINGLE-BLIND METHOD.sh. (10505)
7 or/1-6 (387195)
8 HUMANs.sh. (9533289)
9 ANIMALs.sh. (3970623)
10 9 not 8 (3018353)
11 7 not 10 (364156)
12 CLINICAL TRIAL.pt. (431113)
13 exp Clinical Trials/ (185629)
14 (clin$ adj25 trial$).ti,ab. (124831)
15 ((singl$ or doubl$ or trebl$ or tripl$) adj25 (blind$ or mask$)).ti,ab. (88283)
16 PLACEBOS.sh. (25705)
17 placebo$.ti,ab. (99261)
18 random$.ti,ab. (357426)
19 or/12-18 (787581)
20 19 not 10 (731504)
21 11 or 20 (748271)
22 exp BRONCHITIS/ (22484)
23 acute bronchit$.mp. [mp=title, original title, abstract, name of substance word, subject heading word] (884)
24 exp Respiratory Tract Infections/ (215767)
25 or/22-24 (217540)
26 Anti-Bacterial Agents/ (157181)
27 exp Lactams/ (90537)
28 exp Tetracyclines/ (31342)
29 exp Aminoglycosides/ (97899)
30 exp Glycopeptides/ (37656)
31 exp Macrolides/ (66142)
32 antibiotic$.mp. [mp=title, original title, abstract, name of substance word, subject heading word] (166066)
33 exp alamethicin/ or exp amdinocillin/ or exp amdinocillin pivoxil/ or exp amikacin/ or exp amoxicillin/ or exp amoxicillin-potassium
clavulanate combination/ or exp ampicillin/ or exp aurodox/ or exp azithromycin/ or exp azlocillin/ or exp aztreonam/ or exp bacitracin/
or exp bacteriocins/ or exp brefeldin a/ or exp butirosin sulfate/ or exp candicidin/ or exp carbenicillin/ or exp carfecillin/ or exp cefaclor/
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or exp cefadroxil/ or exp cefamandole/ or exp cefazolin/ or exp cefixime/ or exp cefmenoxime/ or exp cefmetazole/ or exp cefonicid/ or
exp cefoperazone/ or exp cefotaxime/ or exp cefotetan/ or exp cefotiam/ or exp cefoxitin/ or exp cefsulodin/ or exp ceftazidime/ or exp
ceftizoxime/ or exp ceftriaxone/ or exp cefuroxime/ or exp cephacetrile/ or exp cephalexin/ or exp cephaloglycin/ or exp cephaloridine/
or exp cephalosporins/ or exp cephalothin/ or exp cephapirin/ or exp cephradine/ or exp chloramphenicol/ or exp chlortetracycline/
or exp citrinin/ or exp clarithromycin/ or exp clavulanic acid/ or exp clavulanic acids/ or exp clindamycin/ or exp cloxacillin/ or exp
colistin/ or exp cyclacillin/ or exp dactinomycin/ or exp daptomycin/ or exp demeclocycline/ or exp dibekacin/ or exp dicloxacillin/ or
exp dihydrostreptomycin sulfate/ or exp distamycins/ or exp doxycycline/ or exp echinomycin/ or exp edeine/ or exp erythromycin/
or exp erythromycin estolate/ or exp erythromycin ethylsuccinate/ or exp floxacillin/ or exp framycetin/ or exp fusidic acid/ or exp
gentamicins/ or exp gramicidin/ or exp imipenem/ or exp lactams/ or exp lasalocid/ or exp leucomycins/ or exp lymecycline/ or exp
mepartricin/ or exp methacycline/ or exp methicillin/ or exp mezlocillin/ or exp mikamycin/ or exp minocycline/ or exp miocamycin/
or exp moxalactam/ or exp mupirocin/ or exp mycobacillin/ or exp nafcillin/ or exp nebramycin/ or exp nigericin/ or exp nisin/ or exp
novobiocin/ or exp nystatin/ or exp ofloxacin/ or exp oligomycins/ or exp oxacillin/ or exp oxytetracycline/ or exp penicillanic acid/
or exp penicillic acid/ or exp penicillin g/ or exp penicillin g, benzathine/ or exp penicillin g, procaine/ or exp penicillin v/ or exp
piperacillin/ or exp pivampicillin/ or exp polymyxin b/ or exp polymyxins/ or exp pristinamycin/ or exp prodigiosin/ or exp rifabutin/ or
exp ristocetin/ or exp rolitetracycline/ or exp roxarsone/ or exp rutamycin/ or exp sirolimus/ or exp sisomicin/ or exp spectinomycin/ or
exp streptogramin a/ or exp streptogramin group a/ or exp streptogramin group b/ or exp streptogramins/ or exp streptovaricin/ or exp
sulbactam/ or exp sulbenicillin/ or exp talampicillin/ or exp teicoplanin/ or exp tetracycline/ or exp thiamphenicol/ or exp thiostrepton/
or exp ticarcillin/ or exp tobramycin/ or exp troleandomycin/ or exp tylosin/ or exp tyrocidine/ or exp tyrothricin/ or exp valinomycin/
or exp vancomycin/ or exp vernamycin b/ or exp viomycin/ or exp virginiamycin/ or exp beta-lactams/ (211481)
34 or/26-33 (499372)
35 21 and 25 and 34 (4684)
36 limit 35 to ed=20040103-20070201 (761)
37 from 36 keep 1-761 (761)
F E E D B A C K
Data reported on adverse effects
Summary
We would like to draw attention to the misleading statement of authors conclusions for this review. The authors conclusion in the
abstract reads: “Overall, antibiotics appear to have a modest beneficial effect in patients who are diagnosed with acute bronchitis.
THE MAGNITUDE OF THIS BENEFIT, HOWEVER, IS SIMILAR TO THAT OF THE DETRIMENT FROM POTENTIAL
ADVERSE EFFECTS.”
The data reported on adverse effects does not seem to support this conclusion.
Graph 07 showing the number of participants with adverse effects in the antibiotics and control groups illustrates that adverse events
in the antibiotics group reach significance in just one small study (King 1996), and the non-significant pooled estimate is clearly stated
in the results section: “The overall relative risk (RR) of adverse effects was 1.22 (95% CI 0.94 to 1.58).”
We would like to recommend that the authors amend their conclusions to take account of these comments.
Submitter agrees with default conflict of interest statement: I certify that I have no affiliations with or involvement in any organisation
or entity with a financial interest in the subject matter of my feedback.
Reply
We accept that our conclusions are overly pessimistic about side effects from antibiotic therapy. The pooled results from the updated
review changed after inclusion of an additional RCT (Matthys 2000, see Figure 8 of the review), making adverse events less likely. We
acknowledge that we did not change the tone of our conclusions to reflect this greater uncertainty concerning side effects.
We have amended the conclusion in the abstract to reflect the updated results concerning side effects to the following sentence:
“The magnitude of this benefit, however, needs to be considered in the broader context of potential side effects, medicalisation for a
self-limiting condition, increased resistance to respiratory pathogens and cost of antibiotic treatment.”
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Tom Fahey
Lorne Becker
John Smucny
Rick Glazier
Contributors
Paul Garner and Helen Smith
Feedback added 21 May 2005
Correction to updated review
Summary
Dear Authors,
Compared to the version published in the Cochrane Database of Systematic Reviews 2002, issue 2, the current version of the review
included two more studies (Matthys, 2000; Evans, 2003). By consequence, some comparisons (02, 04-07) were updated. Therefore,
the abstract should start with “Eleven studies involving over 1250 patients” instead of “Nine trials involving over 750”. But, more
importantly, except for comparison 07: Adverse effects, the values of the comparisons already mentioned in the abstract still need to
be adjusted, i.e. 05: Not improved by physician’s global assessment at follow-up visit (RR 0.44; 95% CI 0.30,0.65; NNT 10; 95% CI
...) instead of (RR 0.52; 95% CI 0.31,0.85; NNT 14; 95% CI 8 to 50);06: Abnormal lung exam at follow-up visit (RR 0.54; 95% CI
0.41,0.70; NNT 6; 95% CI ...) instead of (RR 0.48; 95% CI 0.26,0.89; NNT 11; 95% CI 6 to 50); Finally, due to the inclusion of
(Matthys, 2000) comparison 02: Night cough at follow-up visit, now shows a significant difference between antibiotics and placebo(RR
0.67; 95% CI 0.54,0.83; NNT 7 ; 95% CI ...) instead of (RR 0.76; 95% CI 0.45,1.30). This comparison should thus be removed
from the statement starting with “There were nog significant differences regarding the presence of night cough, productive cough, ...”
and added to the previous sentence showing the benefits of antibiotic treatment. Given the difficulties in distinguishing upper from
lower respiratory tract infections in daily practice and given the results of the study by Little et al. mentioned as ongoing study, the
conclusions are still justified.
With kind regards.
Submitter agrees with default conflict of interest statement:I certify that I have no affiliations with or involvement in any organisation
or entity with a financial interest in the subject matter of my feedback.
Reply
Thank you for your comments regarding inconsistencies noted in the previous update of the review. The review has been updated again
over the last nine months and these inconsistencies were noted and corrected. The Little study has since been published and is now
incorporated in this new version of the review.
Susan Smith
Tom Fahey
John Smucny
Lorne Becker
Contributors
Samuel Coenen
(Feedback added 01 May 2008)
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WH A T ’ S N E W
Last assessed as up-to-date: 15 January 2014.
Date Event Description
15 February 2014 New citation required but conclusions have not
changed
Review updated and strengthens the conclusion sug-
gesting no evidence to support use of antibiotics in pa-
tients with acute bronchitis. The analysis of adverse ef-
fects has been updated by the addition of data from
the largest study conducted to date and now indicates
a statistically significant rate of adverse effects in the
antibiotic treated groups
15 January 2014 New search has been performed Searches were updated and one of the ongoing trials has
been published and is now included in the review (Llor
2013). We identified one new included study (Little
2013).
H I S T O R Y
Protocol first published: Issue 1, 1996
Review first published: Issue 1, 1997
Date Event Description
1 March 2012 Amended Correction made to Analysis 6.1 ’Clinically improved’ (Figure 1) as error
noted in data entry relating to Stott 1976. This does not change the specific
conclusions for this analysis or the overall conclusions of the review.
6 September 2010 New search has been performed Searches updated and one new trial was included (Nduba 2008). The con-
clusions remain unchanged.
5 August 2010 Amended Contact details updated
30 April 2008 Feedback has been incorporated Feedback and response added
18 December 2007 New search has been performed Searches conducted
11 December 2007 Amended Converted to new review format
22 May 2005 Amended Conclusions changed in the abstract
21 May 2005 Feedback has been incorporated Feedback and response added
25 March 2004 New search has been performed Searches conducted
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(Continued)
29 February 2000 New search has been performed Updated search Issue 4, 2000. No additional trials found, but were able
to obtain unpublished data from three trials that were not included in the
original review. The trials were not included in the first review because the
participants in the trials as a whole did not meet our inclusion criteria.
However, the trials each contained a subgroup of patients that did meet our
inclusion criteria. We were also able to obtain additional unpublished data
from some of the trials that were originally included
27 August 1997 New search has been performed Review first published Issue 4, 1997
Figure 1. Forest plot of comparison: Clinically improved, outcome: number of patients reporting no
limitations or described as cured/well/symptoms resolved or globally improved.
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